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Background: Alzheimer’s disease (AD) is the most common form of dementia and is 
characterized by a progressive loss of memory, judgment, and thinking in older adults. The 
current treatment is cholinesterase inhibitors, which increase acetylcholine at the synapse.  
Medications with anticholinergic (AC) activity are given for a variety reasons including for the 
treatment of comorbid conditions or side effects of cholinesterase inhibitors (ChEIs).   
xii 
 
These drugs inhibit acetylcholine in the brain.  Studies have shown the detrimental outcomes of 
using AC medications with ChEIs in older adults. Moreover, older patients take more 
medications and have an increased risk of developing AC toxicity as these effects are additive.  
The association between AC burden with functional, cognitive, and behavioral outcomes bears 
further evaluation. 
Methods: This study is a retrospective observational study that investigated the effect of AC 
medications on function, cognition, and behavior.  Data was collected from charts on dementia 
patients who resided at Piedmont Geriatric Hospital.  Descriptive statistics and GEE regression 
were performed using MS Excel 2007 and SPSS 18.0.  
Results: There were a total of 83 subjects included in this study with a median age of 77 years 
old and with a median length of stay of 536 days. 33.7% of the patients were taking cognitive-
enhancing medications.  The analysis found that AC burden was not a significant predictor of 
functional, cognitive or behavioral decline.   
Conclusion: The minimal amount of literature on this association, suggests that AC burden may 
have negative consequences on function, cognition and behavior in dementia patients.  The study 
results provided inconclusive evidence about the association of AC burden on poorer functional, 
cognitive and behavioral outcomes.  Future research in this field is needed to determine if there 
is a true association between worsening outcomes and AC burden.   
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Chapter 1 
Introduction 
1.0 Chapter Introduction 
This diversified chapter introduces Alzheimer’s disease, anticholinergic drugs and burden as well 
as the barriers to research.   Dementia, especially Alzheimer’s disease (AD), is a chronic disease 
that lacks a cure.  Cholinesterase inhibitors (ChEIs) are a symptomatic treatment for AD.  Other 
drugs with anticholinergic properties are typically used as treatment for comorbid conditions 
associated with AD.  This second class of drugs, anticholinergic (AC) medications, has been 
associated with negative outcomes in older adults.  There is some evidence and suggestion that 
these AC medications may be associated with negative outcomes in dementia patients as well, 
but the link between dementia and negative effects as a result of anticholinergic properties is not 
well defined due in part to barriers to conducting research in patients with dementia. One 
potential reason for this lack of evidence is difficulty in recruiting older dementia patients to 
participate in studies.   
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the leading cause of dementia in older adults, accounting for 60 to 
80% of all dementia cases.  
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The Alzheimer’s Association estimates that currently over 5.3 million Americans suffer from 
AD and that by 2050 an estimated 11 to 16 million people over the age of 65 will be affected 
(Alzheimer’s Association, 2010).     
AD is a progressive neurodegenerative disorder that has particular clinical and pathological 
changes associated with it.  The disease damages the limbic structures, specifically the 
hippocampus, cholinergic system and neocortical pathways (Maccioni et al, 2009).  Clinically 
this is characterized by a progressive loss of memory, judgment, and thinking in the older 
population.  This disease affects each individual differently.  The most common pattern of 
progression starts with difficulty remembering new information possibly followed by memory 
loss, loss of executive functioning, difficulty in completing familiar tasks, confusion with spatial 
information, problems with language and perception, withdrawal from social activities, and 
changes in personality (Alzheimer’s Association, 2010).  It is suggested that the symptomatic 
course is generally 5 to 10 or more years from the time that the memory deficits appear.  Other 
evidence suggests that a seven year pre-clinical decline occurs (Shah et al, 2008).   
The mechanism of neurodegeneration is not well understood, but it is suggested that the 
neurodegenerative process starts with damage to the synaptic terminals that leads to eventual 
neuronal loss (Maccioni et al, 2009).  Loss of the synapse occurs and is correlated with cognitive 
decline.  This damage is caused by the formation and proliferation of plaques consisting of 
amyloid β (Aβ) peptides and neurofibrillary tangles composed of tau proteins (Maccioni et al, 
2009).   
The disease does not have a definitive cause and several theories have been developed to attempt 
to understand and explain the basis of Alzheimer’s disease.  The most widely held theory is the 
 3 
 
Amyloid hypothesis in which AD is caused by the formation of plaques made by the deposition 
of beta-amyloid peptides (Aβ) in brain tissue.  These plaques are misfolded from the natural 
occurring amyloid peptides.  In addition, it is suggested that the formation of neurofibrillary 
tangles by tau proteins is a result of the imbalance of Aβ production and clearance (Hardy et al, 
2002).  The amyloid hypothesis is compelling because the gene for the amyloid beta precursor 
APP is located on chromosome 21.  The regions linked to one type of familial AD are also on 
chromosome 21.  Furthermore, Down syndrome patients who have an extra copy of this 
chromosome present with disorders similar to AD by the age of 40.   Moreover, research has 
found that there are genetic defects in the genes that code for APP in some types of familial AD.  
In addition, genetic defects are also found in certain proteins, presenilin 1 and 2 which produce 
the enzyme that produces one form of Aβ.  It has been shown that mutations in presenilin 1 & 2 
increase the levels of Aβ (Ropper et al, 2005).     
One of the oldest hypotheses is the cholinergic hypothesis in which AD symptoms are caused by 
a deficiency in the production of acetylcholine. This was based on the work of Whitehouse et al 
in 1982, who found a selective loss of basal forebrain neurons in AD patients (Shah et al, 2008).  
These neurons are the major source of cholinergic innervations in the cerebral cortex. 
Cholinergic innervations of the brain extend to the cortical and hippocampal regions.  These 
regions are important to the processes of memory, language, and visuospatial skills.  Cholinergic 
neurons develop from the nucleus basalis of Meynert to both the hippocampus and the cortex.  
Transmissions through these innervations are very important in normal cognitive functioning 
(Kay et al, 2005A).  The degeneration of the cholinergic circuits and impaired cholinergic 
transmission has been associated with cognitive dysfunction. Therefore, the first-generation anti-
Alzheimer's medications are based on this hypothesis and work to preserve acetylcholine 
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activity.  This class of drugs reversibly inhibits the enzyme acetylcholinesterase, which is 
responsible for the breakdown of acetylcholine at the synapse into choline and acetate.  The 
inhibition of this enzyme prolongs the activity of the existing acetylcholine at the synapse 
thereby perpetuating the signal longer.  There is some evidence that these drugs may stabilize the 
disease for a short period of time, but there is no evidence of disease modification (Shah et al, 
2008).  The proposed mechanism of stabilization is based on the β-amyloid-cholinesterase-cyclo-
oxygenase-2 cycle.  The idea is that β-amyloid increases the expression of both AChE and cyclo-
oxygenase 2 (COX-2) in the brain.  The inhibition of AChE by ChEIs increases the release of 
APP and reduces β-amyloid deposits as well as COX-2 expression, which is suggested to cause 
inflammation in AD (Giacobini, 2001).  This class of medications, acetylcholinesterase inhibitors 
(AChEI), contains four drugs that are still on the market.  The first is tacrine that is rarely used as 
it requires dosing four times per day and has been linked to hepatotoxicity.  The other three drugs 
include donepezil, galantamine and rivastigmine.  These drugs have greater efficacy compared to 
tacrine.  The most commonly prescribed AChEI is donepezil, which has indications for mild 
through severe disease.  The other AChEIs have an FDA approved indication only for mild and 
moderate disease.   
There is a second class of drugs that is used for the treatment of AD.  This class, N-methyl-D-
aspartate (NMDA) receptor antagonists are used based on the premise that the release of 
glutamate in the CNS may play a role in excitotoxic reactions thereby leading to cell death 
(Koda-Kimble et al, 2005).  Memantine, an uncompetitive antagonist that works by blocking 
glutamatergic neurotransmission by antagonizing this receptor, is the only medication of this 
class currently on the market in the US.  It has an indication for monotherapy in moderate to 
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severe disease and studies suggest when combined with AChEIs there is more improvement in 
cognition and ADLs than with memantine alone.  
A review of the clinical trial data by a Cochrane review in 2006, found that after treatment for 6 
months with the three AChEIs, there were some improvements in cognitive functioning, 
behavior and function.  The positive improvements were mild or small with a 2-3 point decrease 
on the ADAS-Cog (Birks, 2006), the gold-standard in measurement of cognitive functioning in 
AD trials.  These mild improvements on assessments do not translate to significant clinical 
improvements. Furthermore, adverse events were not uncommon.  There was a significant 
difference in the percentage of treatment patients, 29%, who withdrew due to adverse events 
compared to the placebo group, 18%.  There were forty-seven types of adverse events that 
occurred among the several AChEI trials.  The most commonly reported events include 
abdominal pain, anorexia, abnormal dreams, asthenia, diarrhea, dizziness, fatigue, headache, 
insomnia, muscle cramp, nausea, syncope, tremor, peripheral edema, vertigo, weight loss and 
vomiting.  These adverse events occurred significantly more in treatment patients than in placebo 
(Birks, 2006). Moreover, in a study by Gill et al it was found that as many as 51% to 78% of the 
older adults assessed would not have been eligible to participate in the ChEI clinical trials.  
Additionally, they found that their cohort was older and more likely to be living in long-term 
care compared to the clinical trial participants (Gill et al, 2004).  Finally, cost-effectiveness 
studies that have been completed have shown that these medications may not be cost-effective.  
Also, the cost-savings associated with reducing the time spent in full-time care does not balance 
the cost of the treatment (Loveman et al, 2006).   
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1.2 Anticholinergic Medications: 
1.2.1 Definition and Exposure 
Anticholinergic (AC) medications play an important role in patients with Alzheimer’s disease as 
they are frequently added to medication regimens to treat comorbid conditions.  These drugs, as 
the name would suggest, antagonize cholinergic receptors.  There are two types of cholinergic 
receptors, muscarinic and nicotinic.  There are five subtypes of muscarinic receptors M1-M5; 
three of which are important in cognitive functioning (Katzum BG, 2001).  These include M1, 
M2 and M4, which are located CNS.  All of the muscarinic receptor subtypes are distributed 
throughout the brain.  The M1 subtype is most abundant in the CNS, especially the hippocampus, 
neocortex, and the neostriatum.  The M2 receptor is located throughout the brain and the M4 
specifically in the neostriatum.  The M5 are localized to the hippocampus with projections in the 
substantia nigra, pars compacta and ventral tegmental nuclei.  The M3 subtype is the only one 
that has low levels in the brain.  Pharmacological studies that investigated the role of these 
receptors found that in M1 knockout mice there are impairments in spatial memory and severe 
deficits in working memory.   In M2 knockout mice, impaired behavioral tasks requiring 
working memory and impaired regulation in cholinergic functioning was seen.  Furthermore, 
studies have shown that blockade of M1 and M2 receptors is associated with increased amyloid 
plaques and neurofibrillary tangles compared to normal controls (Kay et al, 2005A; Perry et al, 
2003).  Other studies have linked M4 receptors to regulation of acetylcholine levels.   Moreover, 
these three subtypes may be involved in mediating cholinergic effects on motor and sensory 
processes (Kay et al, 2005A).  Additionally, one study suggested that antimuscarinic activity 
may increase amyloid plaques.  This is based on evidence that activation of M2 receptors 
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increases the amyloidogenic activity of two important secretases that are known to cleave APP 
into a more aggregative form of amyloid.  A study in Parkinson’s disease patients found that 
chronic use of antimuscarinics was associated with higher rates of plaque and tangle formation 
(Perry et al, 2003).   
The aging process leads to a cholinergic deficit that may explain some of the increased 
sensitivity to medications that block muscarinic receptors. There is some evidence that there are 
age-related declines in M1 receptors.  One study found that the density of the M1 receptor 
subtype was 50% lower in an 82 year-old compared to a 19 year-old (Kay et al, 2005A).   In 
addition, age-related physiologic changes affecting drug absorption, distribution, metabolism and 
elimination processes may alter responses to drugs compared to younger counterparts.  
Specifically, muscle metabolism is decreased and leads to increased fat deposition (Han et al, 
2008), which affects the distribution of drugs in the body.  In terms of drug metabolism, one 
study suggests that in older adults over 70, there may be as much as a 30% decrease in 
metabolism (Sotaniemi et al, 1997).  Elimination processes are altered with age, chronic disease 
and certain medications. Hepatic clearance is more likely to be prolonged with age, specifically 
in drugs that undergo phase 1 metabolism.  Those that undergo phase 2 only, are not typically 
affected.  In renal elimination, it is estimated that creatinine clearance decreases at an average 8 
ml/min/decade after the age of 30 (Ruscin, 2009).  This change decreases renal elimination of 
some medications.  Therefore there is an increased exposure to a drug and its metabolites in an 
older adult. Furthermore, there is decreased functioning of cholinergic brain receptors and 
increased permeability to the blood brain barrier (BBB) (Han et al, 2008).  In younger 
counterparts, the BBB is made up of endothelial cells with tight junctions, which only allow 
small, unpolarized, lipid-soluble molecules to pass through.  As a person ages, these cells begin 
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to shrink and the tight junctions allow for the creation of channels which allow larger, more 
polarized molecules into the brain.  Other factors such as stress, comorbid diseases and some 
medications may increase the permeability of the BBB.   
There are several medications with AC properties and this is shown in Table 1, which is 
compiled from the literature (Zarowitz et al, 2007; Ness et al, 2006; Lechevallier-Michael N  
et al, 2004).  
Table 1: Sample list of medications with AC properties 
Generic Name Brand Name Generic Name Brand Name 
Antihistamines   Benzodiazepines   
Chlorpheniramine Chlor-Trimeton Alprazolam Xanax 
Dexchlorpheniramine Polaramine Chlordiazepoxide Librium 
Diphenhydramine Benadryl Diazepam Valium 
Hydroxyzine Vistaril/Atarax Flurazepam Dalmane 
Promethazine Phenergan Oxazepam Serax 
Fexofenadine Allegra Corticosteroids   
Meclizine Antivert Dexamethasone Decadron 
Loratadine Claritin Hydrocortisone Cortef 
Doxylamine Unisom Prednisolone Orapred 
Antimuscarinics   Gastrointestinal   
Oxybutynin Ditropan Atropine   
Tolterodine Detrol Belladonna Alkaloids Donnatal 
Darifenacin Enablex Cimetidine Tagamet 
Solifenacin Vesicare 
Clindinium-
chlordiazepoxide Librax 
Trospium Sanctura Dicyclomine Bentyl 
Cardiovascular   Hyoscyamine Levsin/Levsinex 
Captopril Capoten Metoclopramide Reglan 
Digoxin Lanoxin Rantidine Zantac 
Diltiazem Cardizem Immunosuppression   
Dipyridamole Norpace Azathioprine Imuran 
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Generic Name Brand Name Generic Name Brand Name 
Furosemide Lasix Cyclosporin Neoral/Sandimmune 
Hydrochlorothiazide Microzide Antibiotic   
Isosorbide 
mononitrate Imdur Ampicillin   
Nifedipine Adalat/Procardia Cefoxitin Mefoxin 
Triamterene Dyrenium Clindamycin Cleocin 
Warfarin Coumadin Cycloserine Seromycin 
Anticonvulsants   Gatifloxacin Tequin 
Phenobarbital   Gentamicin Garamycin 
Antidepressants   Moxifloxacin Avelox 
Amitriptyline Elavil Piperacillin/Tazobactam Zosyn 
Desipramine Norpramin Tobramycin Nebcin 
Doxepin Sinequan Vancomycin Vancocin 
Imipramine Tofranil Muscle Relaxants   
Mirtazipine Remeron Carisoprodol Soma 
Nortriptyline Aventyl/Pamelor Chlorzoxazone Paraflex 
Trazodone Desyrel Cyclobenzaprine Flexeril 
Paroxetine Paxil Metaxalone Skelaxin 
Phenelzine Nardil Methocarbamol Robaxin 
Antipsychotics   Parkinson’s Disease   
Clozapine Clozaril Amantadine Symmetrel 
Olanzapine Zyprexa Benztropine Cogentin 
Thioridazine Mellaril Trihexyphenidyl Artane 
Narcotic Analgesics   Methyldopa Aldomet 
Codeine   Respiratory   
Oxycodone 
OxyContin, 
Percodan Theophylline 
Theo-
24/Uniphyl/Theolair 
Hydrocodone Vicodin     
 
As shown there are several medications, including warfarin and antibiotics, that one would not 
typically consider as having AC properties.  While relatively comprehensive, this list is only a 
sample as many medications are not included including newer ones such as fesoterodine.   
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1.2.1.2 Anticholinergic Burden 
The term anticholinergic burden (AC burden) refers to the cumulative effect of taking multiple 
medications that block muscarinic receptors in the cholinergic nervous system.  As discussed in 
the previous section, AC medications are believed to be hazardous to older adults, especially 
those with dementia.  There is an additional issue of the cumulative effects of these medications.    
The concern of AC toxicity resulting from cumulative AC burden of multiple medications is a 
real issue for older adults (Kay et al, 2005A).  The evidence in the literature provides some 
insight as to the seriousness of AC burden.  Han et al found that AC burden was significantly 
associated with poor performance on memory and executive tasks, specifically the Hopkins 
Verbal Recall Test (HVRT) and the Instrumental Activities of Daily Living (IADL) (Han et al, 
2008).   A study by Ancelin et al showed that continuous use of AC medications for greater than 
one year was independently associated with poorer performance on attention, short-term memory 
and visuospatial construction (Ancelin et al, 2006).  Burden is not an issue relating to only long-
term use of medications with AC properties.  Short-term studies show that the cumulative burden 
effects in older adults taking AC drugs for at least two weeks was associated with declines in 
visual memory, verbal fluency, global cognitive function, and on activities of daily living scales 
(Han et al, 2008).  Recent studies have found that the cumulative effect of AC medications is 
strongly associated with falls in hospitalized older adults (Nebes et al, 2007).  The literature 
suggests that older adults in the community are also at risk as many medications that are most 
commonly prescribed have antimuscarinic properties (Lechevallier-Michael et al, 2004).  Also, 
many older adults use over the counter drugs with AC effects (Nebes et al, 2007).   
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1.2.1.3 Factors Influencing AC Burden 
There are many factors that can influence AC burden including pharmacokinetic and 
pharmacodynamic changes, polypharmacy with medications that have AC properties, drug 
interactions, comorbid disease states, especially dementia, specific drug exposure and the 
integrity of the blood brain barrier.   Polypharmacy or the use of multiple medications is a 
common problem in the older adult population.  As mentioned earlier, older adults have an 
increased sensitivity to AC adverse effects and the possibility of additional AC medications may 
augment the consequences.  In many situations, older adults see multiple physicians who 
prescribe multiple medications and to compound the problem they may not always go to the 
same pharmacy to get the prescriptions filled.  Furthermore, the older adults may not tell their 
doctors about the other medications that they have been prescribed by another physician.  This 
situation has the potential to lead to serious drug interactions and anticholinergic toxicity.  The 
most common AC medications that older adults may forget to inform their healthcare 
professionals include antidepressants and first generation antihistamines (Kay et al, 2005B).   
First generation antihistamines include over-the-counter medications such as diphenhydramine, 
chlorpheniramine and promethazine that are commonly found in allergy, cold/flu, sleep and 
“PM” pain medications.   Cognitive impairment is an important factor in determining the extent 
of AC burden and also increases the risk of receiving an AC medication (Lechevallier-Michael et 
al, 2004). 
1.2.1.4 Determination of Anticholinergic Burden 
Determination of AC activity has been around for several decades due to the numerous pesticides 
and chemical weapons that irreversibly inhibit acetylcholinesterase, thereby resulting in the 
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depletion of acetylcholine. Techniques for assessing AC activity are summarized in Table 2.  
Serum Anticholinergic Activity (SAA) radioreceptor assay is the laboratory assay that is the gold 
standard for measuring anticholinergic burden.  This method is currently the most direct method 
of cumulative anticholinergic measurement, but is not practical in the clinical arena (Kolanowski 
et al, 2009). In this assay, AC medications and metabolites in serum are added to rat brain 
homogenate and competitively inhibit the binding of radiolabelled 3H- quinnuclidinyl benzilate 
(3H-QNB), a cholinergic agonist.  3H-QNB binds with high affinity to all of the muscarinic 
receptor subtypes.  The amount of 3H-QNB displaced is used to quantify the cumulative amount 
 of AC activity (Nebes et al, 2007).  
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Table 2: Methods of Burden Determination 
Method Year Basis Rating Scale Calculation Evidence 
Practical in Clinical 
Setting 
Serum 
Anticholinergic 
Activity (SAA) 
1970's 
Radio-receptor 
Binding Assay 
n/a 
Amount of 3H-QNB 
displaced 
Gold Standard No 
Anticholinergic 
Burden Scale 
(ABS) 
2002 
Atlas of 
Psychiatric 
Pharmacotherapy 
0-5 sum of all drug scores 
AC burden 
significantly 
associated with 
falls 
Yes 
Anticholinergic 
Drug Scale 
(ADS) 
2006 SAA 0-3 sum of all drug scores 
AC burden 
associated with 
SAA values 
Yes 
Anticholinergic 
Rating Score 
(ARS) 
2008 
Expert based; 
disassociation 
constant for 
cholinergic 
receptor, rate of 
AC adverse 
events, and the 
literature 
0-3 sum of all drug scores 
ARS score was 
associated with 
an increased risk 
of 
anticholinergic 
adverse effects 
Yes 
Clinician Rated 
Anticholinergic 
2008 Expert based; 
reported AC 
0-3 sum of all drug scores 
AC burden was 
significantly 
associated with 
Yes 
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Method Year Basis Rating Scale Calculation Evidence 
Practical in Clinical 
Setting 
Scale activity decreased 
executive 
functioning and 
increased 
memory 
impairment 
Anticholinergic 
Cognitive Burden 
(ACB) 
2009 
Expert-based;  
severity of drug’s 
AC activity on 
cognition using a 
scale based on the 
literature between 
1997 and 2007 
0-3 sum of all drug scores 
AC burden not 
associated with 
engagement or 
mental status 
Yes 
Drug Burden 
Index (DBI) 
2009 
FDA Approved 
doses 
n/a 
[(sum of daily doses)/ 
(sum of daily doses + min 
efficacious daily doses)] 
AC burden was 
associated with 
worsening 
function using 
gait speed and 
grip strength 
Yes/No 
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The binding is expressed in atropine equivalents, with higher atropine equivalents conveying a 
greater likelihood of AC properties of drugs and metabolites in serum (Nishtala et al, 2009).  
Research has shown that the use of SAA is an appropriate method to calculate AC burden in 
older adults.  In a study of community-based elderly aged 70+, SAA was associated with the 
Mini-Mental State Exam (MMSE) scores.  Those who had SAA levels in the 90th percentile and 
greater were 13 times more likely to have MMSE scores that were less than 24/30 compared to 
subjects who had no measurable SAA. Even low SAA was associated with cognitive impairment 
(Kay et al, 2005A; Mulsant et al, 2003). 
The assay does have limitations however. Serum is not always representative of what is 
occurring in the brain.  Plaschke et al investigated this relationship between AC activity in the 
cerebral spinal fluid (CSF) and blood.  A competitive radioreceptor binding assay was used.  
They found that mean AC levels in the blood were 2.4 ± 1.7 pmol/mL and 5.9 ± 2.1 pmol/mL 
atropine equivalents in the CSF.  AC activity was found to be 2.5-fold higher in the CSF.  There 
was a significant linear correlation between blood and CSF levels.  Therefore, it was determined 
that SAA does reflect central anticholinergic activity (Brecht et al, 2007). Furthermore, SAA 
does not appear to be affected by surgery or clinical care (Brecht et al, 2007). Contrary to these 
results, Mach et al found that SAA was elevated in patients who were delirious compared to 
those who were not (Mach et al, 1995).  Therefore SAA may be affected by acute illness.   Also, 
SAA is a tool that may be used to assess delirium.  A study by Flacker et al. used a radioreceptor 
assay to assess delirium in 67 patients.  They found that delirium was associated with higher 
SAA and there were a higher number of delirium symptoms associated with a higher SAA 
(Flacker et al, 1998).  Other studies have used SAA to investigate the association of AC burden 
with functional outcomes.  In the study by Nebes et al, participants were divided into low, 
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medium, and high SAA groups (Nebes et al, 2007).  Participants underwent a walking 
assessment in which they had to walk a 15-foot course on carpet.  Response time was assessed 
by pressing a button when they saw a one centimeter dot appear on a computer screen. After 
controlling for sex and age, the high SAA group (>1.9 pmol/mL) had significantly slower walk 
times and response times.  It is suggested that the psychomotor slowing that occurs at high SAA 
levels may predict balance issues and falls (Nebes et al, 2007).  Furthermore, several studies 
have shown the association between SAA and adverse CNS effects (Nishtala et al, 2009).  This 
includes a study by Chew et al who used SAA to measure AC activity of the 107 most frequently 
dispensed medications used by older adults in long term care (Chew et al, 2008).  
Pharmacokinetic data was used to estimate the dose and AC activity relationship.  The 
investigation found that 39 of the 107 medications showed detectable AC activity.  Medications 
found to have a high AC activity, which was determined as a concentration of greater than 15 
pmol/mL atropine equivalents, included amitriptyline, doxepin, clozapine, thioridazine, atropine, 
dicyclomine, L-hyoscyamine, and tolterodine.  All 13 of the drug classifications evaluated had at 
least one drug that had AC activity at its therapeutic dose (Chew et al, 2008).  While SAA is an 
appropriate way of determining AC burden, it is not the most practical in clinical settings.  This 
laboratory assay is lengthy and requires a blood sample.  This may prove difficult in older adults, 
especially those with dementia.  Moreover, SAA cannot be readily performed in nursing homes, 
assisted living facilities and other locations where a calculation of burden would be helpful to 
prevent negative drug consequences because the assay is not widely available in commercial 
clinical laboratories.  
Recently, several rating scales to assess burden in an efficient way have been developed.   One 
such scale is the Anticholinergic Burden Score (ABS).  The ABS is an additive score based on 
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quantitated AC effect of each psychotropic compound a patient receives.  This quantitated AC 
effect is rated on a scale of 0 (no AC effect) to 5 (highly AC effect) based on information 
published in the “Atlas of psychiatric pharmacotherapy” (Shiloh et al, 1999).   For example a 
medication such as amitriptyline has a value of 5 and risperidone or fluoxetine is a 1.  In a study 
by Aizenberg et al, ABS was used to evaluate the effect of AC burden on falls.  The ABS for 
each of the 102 patients was calculated.  There were 34 patients who had a recorded fall and the 
ABS was calculated on this day.  The mean ABS score for all of the patients was 2.68 ± 1.8 and 
for those patients that suffered falls was 3.25 ± 2.2.  This value was significantly different from 
those who did not suffer a fall. This scale does not take the dose or dosing regimen into account.  
In addition, the basis for the rating scale is from a book and on the pharmacological mechanism 
of action (Aizenberg et al, 2002).  Additionally, the referenced version of the text was not 
available.  Therefore, the method of how the quantitated AC effect was determined was not 
understood.  
Another scale is the clinician-rated anticholinergic score.  This scale is different from the 
previous one in that it incorporates expert opinion.  This scale was originally developed to assess 
potential effects of AC medication use on the severity of delirium symptoms.  Scores range from 
0, no effect, to 3, strong effect.  The rating procedure and resultant AC drug list were based on 
the Summer’s Drug Risk Number (DRN), where 62 medications were classified as 0 to 3.  This 
was published in 1978.   To update the list, 340 medications with reported AC activity as well as 
those used in the study population from the Han et al study in 2001 were included.  Then 3 
geriatricians independently rated the AC effect of each medication from 0 to 3 based on their 
clinical experience, knowledge of the properties of the drugs and the American Hospital 
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Formulary Service system.   The median of the 3 ratings were adopted.  All medications were 
counted, both AC and non-AC, in this method.  Previous studies have shown that this rating 
scale has good criterion and predictive validity with the SAA.  There were 544 participants 
enrolled in the Han et al. study, of which 342 or 62.9% used AC medications (Han et al, 2008).  
The study evaluated the longitudinal effect of cumulative AC drugs on memory and executive 
functioning.  The mean clinician-rated AC score was 1.3 ± 1.5 for all 342 participants.  The most 
frequently used medications that had a score of 2 or 3 included ranitidine, amitriptyline and 
fexofenadine.  AC burden was significantly associated with decreased executive functioning and 
increased memory impairment (Han et al, 2008).   
An additional scale was developed by Rudolph et al to assess the risk of adverse drug events 
(ADE) caused by AC medications.  ADEs included central effects such as falls, dizziness, and 
confusion and peripheral effects such as dry mouth, dry eyes, and constipation.  The 
Anticholinergic Risk Scale (ARS) ranks medications with AC potential on a scale of 0, limited or 
no AC potential, to 3, very strong AC potential.  This rating scale is similar to the clinician-rated 
AC scale in terms of the scoring and the use of experts.  Specifically, geriatricians and geriatric 
pharmacists determined the rank of each AC drug.  These experts reviewed the disassociation 
constant for the cholinergic receptor, rate of AC adverse events, and the medical literature for the 
most prescribed medications (Rudolph et al, 2008).  Rudolph et al. conducted a two part study; 
the first was a retrospective review of medical records for AC adverse effects and for 
medications included on the ARS. The second part was a medication reconciliation and review 
of the documented AC adverse effects.  The study found that a higher ARS score was associated 
with an increased risk of AC adverse effects for both cohorts (Rudolph et al, 2008).   
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The Anticholinergic Cognitive Burden (ACB) Scale is the third scale that is based on evidence in 
the literature and expert clinician input (Kolanowski et al, 2009).  Additionally, it has a focus on 
central AC effects only.   It is an expert-based index that classifies the severity of a drug’s AC 
activity on cognition using a scale that is based on a review of the literature between 1997 and 
2007.  Specifically studies that measured the AC activity of drugs and their cognitive effects 
were reviewed.  The collected list of medications were then reviewed by an expert 
interdisciplinary team and categorized as mild, moderate, or severe.  These three ratings were 
then translated to 1, 2, and 3.   Total ACB was calculated by summing the ACB scores of all 
scheduled drugs prescribed for an individual.  The study by Kolanowski et al. used this method 
to determine the association of AC burden and engagement in activity in nursing home residents 
(Kolanowski et al, 2009).  The study found that 81.6% of the Pennsylvania nursing home 
patients took at least 1 AC drug.  Additionally, 56.3% were prescribed two or more AC drugs.  
There were a total of 28 AC medications that the patients were taking with furosemide and 
metoprolol as the most commonly prescribed.  The authors concluded that decreased mental 
status was associated with engagement outcomes, but AC burden scores were not (Kolanowski et 
al, 2009).  
Carnahan et al also developed a rating scale, the Anticholinergic Drug Scale (ADS), using 
ratings of 0 to 3, with level 0 = no known AC properties; level 1 = potentially AC as evidenced 
by receptor binding studies; level 2 = AC adverse events sometimes noted, usually at excessive 
doses; and level 3 = markedly AC (Carnahan et al, 2004).  This quantification of AC burden was 
found to be significantly associated with SAA.  Their study also supported the separation of ACs 
into categories based on AC potency.  Overall, the findings of Carnahan et al suggest that ADS 
may be a tool for assessing AC burden (Carnahan et al, 2004).   This tool is unique in that it 
 20 
 
includes both as needed medications, PRN, and scheduled.  In addition, the authors replicated the 
study, but with modifications to evaluate the association with SAA.  The modifications included 
adjusting for dose.  The maximum recommended daily dose for each medication on the list was 
determined using the product labeling approved by the Food and Drug Administration.  The 
maximum dose was compared to the dose that the participants were taking.  Weights were 
applied to the participant’s dose and ranged from 1 to 4.  For instance, if the dose was less than a 
third of the maximum then it was weighted as 1 and if it was greater than the maximum 
recommended daily dose then it was weighted as 4.  With this modification, the analyses found a 
significant association with SAA, but not significant compared to the non-modified scale 
(Carnahan et al, 2006).  While not significant in this study, dosing still explained more of the 
variation seen by the model than by not including it.  Furthermore, dosing is important in 
calculating burden as a higher dose leads to more exposure and a greater level of AC activity.    
The last and most recent scale is the Drug Burden Index (DBI).  The DBI measures overall 
exposure to medications with AC and sedative properties.  This scale includes the daily dose of 
the AC medications and the minimum efficacious daily dose approved by the FDA.  The total 
drug burden is equal to the sum of the daily dose for a medication divided by the sum of the 
minimum efficacious daily dose and the daily dose, for both sedatives and ACs.  All 
medications, except topical ones without significant systemic effects were included.  In the study 
by Hilmer et al, the index was used to evaluate the relationship between physical and cognitive 
performance and medication use (Hilmer et al, 2009).  The study found that higher drug burden 
was associated with worsening function using gait speed and grip strength.   Moreover, a one 
unit increase in the DBI predicted a significant decrease in gait speed of 0.04 m/s, which is more 
significant than the additional decline in physical or mental comorbidity (Hilmer et al, 2009).   
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While the use of laboratory measurements that measure AC activity in the CSF is the best 
followed by a tool such as SAA, it is not practical in most clinical settings.  In addition, it is not 
only time-consuming but also expensive.  Furthermore, alternative methods such as the use of 
one of the many scales may be more appropriate for special populations such as patients with 
dementia.  All of the scales except for the DBI do not take into consideration of the dose.  
Additionally, only the ABS and the DBI do not use a 0/1-3 scale to categorize the medications.  
While the DBI has significant benefits over the other scales as it takes into consideration the 
dose, it is more difficult and time-consuming compared to the other scales.  Therefore it may not 
be entirely practical in a busy long-term care or hospital setting.  When the other scales are 
compared against each other, the ABS is advantageous as it provides a wider scale in which to 
categorize drugs (0-5), but its basis is a textbook.  The Clinician Rated Anticholinergic Scale and 
the ARS are almost identical.  The ACB is different by including only those with central effects, 
this a disadvantage compared to the others.  The ADS is older compared to the other scales 
except for the ABS, and is based on the SAA, which while it is an imperfect measurement, it is 
still better than using expert opinion alone or not including AC potency as a component of 
burden measurement.   
1.2.2 Prevalence of Use 
Several studies have shown that older adults are at greater risk of developing negative side 
effects from prescribed and over the counter medications that have AC properties. Furthermore, 
in some cases these side effects may be attributed to worsening dementia or the increase risk of 
cognitive impairment, falls and functional decline (Robinson et al, 2009; Han et al, 2008).  These 
negative cognitive effects include impairment in working memory, episodic memory, processing 
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speed and praxis.  Moreover, use of AC medications is a significant predictor of overall 
performance on general activities, mild cognitive impairment and delirium (Chew et al, 2008).  It 
is important to note that AC drugs have both central as well as peripheral side effects, including 
confusion, sedation, loss of concentration, hallucinations, and delirium.  In older adults with 
dementia these effects may be magnified (Modi et al, 2009).  Older adults are more likely to 
have multiple chronic diseases and therefore receive multiple medications.  Also, there is an 
increasing trend of drug usage in older adults, even without the addition of chronic diseases (Han 
et al, 2008).  In many cases more than one AC medication is prescribed to the same older adult.  
Also, they are more likely to receive a medication with AC effects.  Studies for decades have 
shown that older adults receive a large number of medications with AC effects.  A summary of 
the prevalence studies is provided in Table 3.  A study in 1983 found that approximately 60% of 
nursing home patients and 40% of ambulatory patients received a medication with AC properties 
(Feinberg, 1993). More recent studies have indicated that as many as 27% of community 
dwelling adults are using AC medications (Merchant et al, 2009).  Furthermore, a study by Han 
et al. found that more than 30% of nursing home residents take two or more AC drugs and 
estimated that this number was closer to 50% in the general population (Han et al, 2008).  
Another study in France found that the 327 older adults who were continuous AC users had 
poorer performance on cognitive tests at 1 year than non-users (Ancelin et al, 2006).  In the study 
by Han et al, 342 (62.9%) of 544 subjects were using AC medications.  The number of subjects 
using these medications increased to 364 and 378 in the following years.  The mean AC score 
was 1.3 ± 1.5 and a median of 1.0.  The most commonly used AC medications had moderate to 
strong effects.  These included ranitidine, amitriptyline, fexofenadine, nortriptyline, and 
paroxetine (Han et al, 2008).  
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Table 3: Summary of Prevalence Studies 
Author; Year Population Result 
Blazer 2nd
5,902 nursing home 
residents and 5, 861 
ambulatory subjects of 
Tennessee Medicaid 
recipients ≥ 65 YO 
 et al; 
1983 
59% of nursing home residents  
and 23% of ambulatory 
subjects received at least 1 AC 
drug 
Lechevallier-
Michael et al.; 
2004 
1780 subjects aged 70 and 
older, living at home in 
South western France 
13.7% of the subjects used at 
least one drug with AC 
properties 
Ness et al; 2006 
532 patients from the Iowa 
City VAMC 
27.1% used at least 1 AC drug 
Johnell et al; 
2007 
732,228 adults ≥75 YO 
from the Swedish 
Prescribed 
6% were prescribed AC drugs 
Drug Register 
Han et al; 2008 
544 community dwelling 
men ≥ 65 YO with 
diagnosis of hypertension 
62.9% were using AC 
medications 
Lakey et al.; 
2009 
174 recipients of home 
health services in Eastern 
Washington State 
80.0% were using a 
medication with AC effects; 
66.1% were using weak AC 
and 33.8% potent agents 
Olsson et al.; 
2010 
3705 residents in nursing 
homes and special 
dementia units in a 
Swedish county 
20.7% in nursing home used 
AC drugs; 18.5% in dementia 
units. 
Kumpula et al.; 
2010 
1004 residents of a 
Helsinki, Finland long-
term care ward in 2003 
36% mild AC burden (ARS 
score = 1-2); 19% high AC 
burden (ARS score ≥ 3) 
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In addition, Blazer et al. in 1983 determined in their study that between 21% and 32% of elderly 
patients living in nursing homes were using two or more AC drugs. Ten to 17% of nursing home 
residents were using > 3 ACs and up to 5% of nursing home residents were using > 5 ACs. 
Regarding combination medication formulations, the most frequently used combinations 
included thioridazine/benzhexol and thioridazine/chlorpromazine (benzhexol is rarely used now). 
Also, the use of thiordiazine concomitantly with amitriptyline was prevalent, which may signify 
that there was a lack of alarm on the part of the prescribers and other involved healthcare 
professionals about the overall summation of AC effects.  One study found that by administering 
AC medications, delirium could be induced and then reversed by administering cholinergic 
agonists (Han et al, 2008).  Similarly, Spore et al. determined that 43% of elderly patients in 
nursing homes were taking psychotropics (Mintzer et al, 2000). Studies suggest that drugs with 
AC effects may reduce the effectiveness of AChEIs when they are taken together (Carnahan et 
al, 2002).   In addition, the combined use has the potential to increase the rate of cognitive 
decline in patients and affect the severity of delirium symptoms that may be present.  In 
dementia and AD, AC medications are prescribed for the treatment of comorbid conditions 
associated with dementia.  In addition, they may also be used to treat the side effects of AChEIs 
in a prescribing cascade.  Studies have shown that the concomitant use of AChEIs and AC 
medications is not uncommon.  A study by Roe and colleagues found that older adults with 
probable dementia were more likely to use moderate to strong AC medications compared to 
matched controls (Roe et al, 2002).   In addition, Carnahan and colleagues measured the 
prevalence of AC use in Iowa Medicaid beneficiaries over the age of 50 who were on AChEIs.  
They also evaluated the change in use of the ACs when an AChEI was started.   They found that 
approximately 36% of the patients were using both classes at the same time.  In addition, about 
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75% of the AC medications were considered highly AC with known adverse events associated.  
The incidence of AC use when an AChEI was started increased in the study participants 
(Carnahan et al, 2004).   Another study found that 1/3 of community dwelling older adults with 
dementia were taking AChEIs and AC medications concomitantly.  Modi et al in 2004 found that 
46.7% of the Indiana Medicaid population was taking the two classes together.  Furthermore, of 
this concurrent population, 58.1% were taking a medication classified as markedly AC.  H2 
antagonists, respiratory antihistamines and urinary antispasmodics were the three most 
commonly prescribed AC medication classes (Nebes et al, 2007).  Other studies have shown that 
older adults with dementia are at an increased risk of the receiving an AC medication (Gill et al, 
2005).   
It is suggested that the cause for this phenomenon is the side effects associated with AChEIs and 
comorbid conditions associated with AD.  Older, less expensive drugs are more likely to be 
prescribed due to economic reasons or prescription biases.  The older, less expensive drugs 
include tricyclic antidepressants which are known to have high AC effects (Inouye, 1999). Roe 
and colleagues concluded that based on the potential for antagonism between AChEIs and AC 
medications that even short-term use is contraindicated (Roe et al, 2002). Interestingly enough, 
trials for donepezil, rivastigmine and galantamine did not allow participants to be on AC 
medications. Determining whether a patient will develop or experience adverse effects to AC 
medications depends on several factors including total AC load, cognitive functioning, and 
individual pharmacokinetic and pharmacodynamic variability (Roe et al, 2002).  There is some 
evidence in the literature about the effects of concurrent use.  In one study, 69 AD patients taking 
AChEIs and AC meds chronically had greater cognitive decline at 2 years than those not taking 
ACs (Han et al, 2008).  There is some evidence that the concomitant use of AChEIs and AC 
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medications may decrease the effectiveness of AChEIs.  Even with this preliminary evidence it is 
not uncommon for the two medication classes to be prescribed together (Modi et al, 2009).   
In addition, to being more likely to receive an AC medication, the demented population is more 
likely to suffer from adverse events and reactions due to AC medications (Thienhaus et al, 1990). 
It is suggested that demented patients are significantly more vulnerable than non-demented in 
cognitive effects of AC medications, possibly due to the central cholinergic deficiency 
(Doraswamy et al, 2006). In addition, studies have shown that the risk of adverse cognitive 
effects increases with total AC burden or load and that these medications have the potential to 
worsen symptoms (Roe et al, 2002; Tune et al, 2003).  It is possible for a dementia patient to 
suffer from AC toxicity, which is characterized by signs and symptoms of dysfunction of the 
parasympathetic system and the brain.  These signs and symptoms include decreased attention 
span, disorientation, psychotic features and psychomotor agitation.  All of these symptoms can 
lead to functional impairment (Thienhaus et al, 1990).  In a study by Thienhaus et al, demented 
participants displayed significant impairment in association with higher AC serum activities 
compared to non-demented patients (Thienhaus et al, 1990). The AC serum levels that were 
associated with significant deterioration of selected cognitive functions caused no dysfunction in 
the 18 non-demented subjects.  Measures of recognition, concentration and retrieval of 
information (corresponds to deterioration of knowledge memory) all decreased significantly with 
higher AC serum levels (Thienhaus et al, 1990).  Other studies have shown worsening 
performance on reaction time, attention, face and narrative recall, and visospatial and language 
abilities (Doraiswamy et al, 2006).   A study by Jewart et al. showed that when dementia patients 
were taken off AC medications, specifically incontinence medications, they demonstrated better 
performance on tests of mental status and behavior (Jewart et al, 2005).  
 27 
 
1.2.3 Outcomes of Use in Older Adults 
There are over 600 medications that have AC properties (Tune et al, 1999), some with intended 
effects and others that are unintended.  Furthermore, Tune et al. tried to determine serum AC 
activity of the 25 most frequently used drugs in the elderly. They found that 14 of the total 25 
drugs had some level of AC activity. Ten of these drugs, which included ranitidine, codeine, 
dipyridamole, warfarin, isosorbide, theophylline, nifedipine, digoxin, and prednisolone, caused 
significant impairment in recent memory and attention in psychiatrically healthy elderly subjects 
(Tune et al, 1992). Often times, several ACs were given concurrently (Mintzer et al, 2000; Tune 
et al, 1992). Scopolamine is strongly AC and it is suggested that it specifically targets muscarinic 
receptors.  Other medications such as the antibiotic piperacillin, has unintended AC effects.  
According to the package insert, piperacillin is a bactericidal drug that works by inhibiting 
septum formation and cell wall synthesis of bacteria (Zosyn Package Insert, 2009).  The package 
insert does not include the AC properties of this medication.  Yet, validated laboratory assays, 
such as the serum anticholinergic activity assay, SAA, have ascertained that this is the case 
(Mintzer et al, 2000; Tune et al, 1999).  This assay has been shown to be a better predictor of 
cognitive impairment than age or the total number of drugs that a person takes (Chew et al, 
2008).   The lack of knowledge about the AC properties of medications may be due to 
insufficient information about how most prescription and over-the-counter drugs as well as their 
metabolites affect the cholinergic system.  Therefore, just knowing a medication has AC 
properties does not provide the full picture (Chew et al, 2008).   Overactive bladder is a good 
example of this situation.  It is a disease state that is common in older adults with dementia, with 
some estimates as high as 53%.  Other reports place this number between 11% and 90% 
depending on the methods of estimation and the definition of urinary incontinence (Yap et al, 
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2006).   Much of the incontinence in dementia is functional, which refers to incontinence 
associated with physical disabilities, external obstacles or mental disabilities.   Antimuscarinic 
medications are the pharmacological treatment for overactive bladder.  These agents work by 
blocking the effects of acetylcholine at muscarinic receptors, specifically of the bladder.  Hence, 
there is a reduction in the frequency and intensity of involuntary detrusor contractions.  Research 
has shown that the M2 and M3 subtypes are located within the detrusor muscle, specifically the 
M2 receptor predominates with a 3 to 1 ratio.  Furthermore, it is the M3 subtype that is mostly 
responsible for muscle contraction.  While the specific action of these antimuscarinic agents is to 
target the M3 receptors, they have the potential to bind to all of the muscarinic receptors, 
including M2 and M1.  Therefore, they have the potential to cause adverse events.  In addition, 
they have the potential to worsen or negatively impact chronic diseases.  There are reports and 
evidence in the literature of memory loss, confusion and delirium with the use of non-selective 
muscarinic receptor antagonists (Kay et al, 2005A).   Furthermore, these neuropsychiatric 
adverse events may be underreported as they may be considered part of normal aging (Kay et al, 
2005A).    
1.2.4 Outcomes of Use in Dementia 
In dementia patients AC toxicity can result in morbidity and mortality, behavioral symptoms and 
delirium.  Studies have found correlations between serum AC levels and functional disability, 
agitation and delirium (Carriere et al, 2009).  Delirium and confusional states are common in 
dementia and associated with mortality rates up to 40%.  In terms of cost, delirium is estimated 
to account for more than $32 to $152 billion each year, according to a 2008 study (Leslie et al, 
2008).  In addition, there are costs for increased hospital stays, nursing home placement, 
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rehabilitation services and home health care (Inouye, 1999).  Dementia is one of the strongest 
risk factors for the development of delirium.  In addition, the severity of the dementia correlates 
to the risk for delirium.  However, detection of delirium in dementia is only in about 12% to 31% 
of all cases.  It is also known that patients with dementia have a significantly longer episode of 
delirium compared to those who do not have dementia (Lim et al, 2006).  One study showed that 
approximately 40-50% of patients with dementia had persistent delirium for 6 to 12 months 
(McCusker et al, 2003).  Delirium and dementia are both associated with cholinergic 
disturbances, but the difference is that delirium is an acute condition that may occur if a person 
has dementia (Tune, 2001).  There are three types of delirium: hyperactive, hypoactive and 
mixed delirium.  The first and third are often associated with cholinergic toxicity.  Some studies 
suggest that up to 11.5% to 39% of all delirium in AD patients is due to medications.  
Medications that are known commonly to cause delirium include high dose narcotics, 
benzodiazepines and ACs.   In addition, to the medications listed above, lithium has been linked 
to delirium in dementia patients (Alagiakrishnan et al, 2004).  Other outcomes reported in studies 
include falls and geriatric syndromes (Tune et al, 1999).  Therefore, the use of AC medications 
with AChEIs in patients with AD has the potential for serious negative outcomes and may 
decrease overall effectiveness of AChEIs. 
1.3 Barriers to Research Participation in Alzheimer’s Disease Studies 
The research that has been conducted and continues to be conducted in this area is mostly 
observational.  According to the current standards, a randomized controlled interventional study 
to reduce AC burden would provide a more definitive conclusion on the impact of AC burden on 
dementia patients.   One reason that these studies have been difficult to perform is patient 
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recruitment.  Recruiting patients is a difficult process and there are many barriers that need to be 
overcome for this to occur.  This section will discuss the barriers associated with recruiting older 
adults to participate in clinical studies.   
Several studies have documented that older patients are underrepresented in clinical research.  
There are a growing number of older adults in the population, which represents a serious 
dilemma for translating research into clinical practice (Marcantonio et al, 2008). This is apparent 
in Alzheimer’s research as well.   Unfortunately, recruiting any sample of older adults, especially 
AD participants, into clinical research is difficult, time consuming, and expensive.  Some studies 
have investigated the reasons behind low participation and found that older adults who refuse to 
participate in research tend to be male, to be older, and belong to a lower income group (Arean et 
al, 1996).  This is true for AD studies as well.  In a 1997 study by Schneider and colleagues the 
entry criteria for industry sponsored AD clinical trials preferentially selected wealthier, more 
educated and white individuals (Olin et al, 2002).  Research has also identified several barriers 
that exist to older adult and Alzheimer’s disease participation in research, but population size and 
availability are not issues.  Barriers can be divided into universal, minority, and researcher 
specific.   
1.3.1 Universal Barriers 
There are many universal barriers including spousal support, location, transportation, caregivers, 
the design of the research project, and knowledge of the study.  Universal barriers include lack of 
spousal support.  Interviews show that if the spouse does not approve of the study or the research 
than the possible participant will not volunteer.  Approximately 55% of potential participants 
indicated that they would decline if their spouse was not interested or did not approve 
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(Marcantonio et al, 2008).  For minorities, not involving the family or the spouse in the study and 
the recruiting process may lead to fear and distrust of the research. Research has shown that as 
many as 32% of potential participants refused to participate in research because their families 
and physicians discouraged them (Arean et al, 1996).  Another barrier is location and 
transportation, traveling to a hospital or a place that is not a residence may lead to a participant 
declining.  In a study by Marcantonio et al in 2008, 98% of the 50 older adults surveyed declined 
participation in a study if they had to go to a hospital (Marcantonio et al, 2008).   For some 
participants the research projects may not be held in communities where they live.  Physical 
limitations such as disabilities and health concerns as well as living in unsafe areas may preclude 
participation.  It is well known that older adults tend to have more health problems and be 
disabled compared to younger counterparts.  In addition, those with dementia are more likely to 
have other comorbid conditions and require other transportation.  Also, many settings may not be 
ideal as participants may not want their friends and families to know that they are participating in 
research or that they have a specific condition.   In a 1993 study by Arean et al, 99% of the 
referrals from a senior center preferred participating in a university setting because they were 
afraid that their friends would find out (Gelman, 2010).  Another factor is care-giving, in which 
some older adults may be caregivers from their own aging parents, spouses, or children.  This 
may hinder their ability to take time to travel to a hospital site or even afford transportation 
(Marcantonio et al, 2008). In addition, Marcantonio and colleagues found that type of research 
also plays a role.  Research that involves an invasive procedure is less likely to acquire 
participation. Of the 50 participants interviewed 61% declined if a lumbar puncture was included 
(Arean et al, 1996).   Even more basic than the type of research is knowledge about the project.  
Many potential participants may not even be aware of the opportunities for research. Advertising 
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in older adult specialty newspapers or in local senior centers may be a useful method.  Enlisting 
the help of physicians and other healthcare professionals may also be useful.  For minorities, 
having a community leader that they trust disseminate the information about the study or 
translating the advertisements in native languages may overcome this barrier.  Another common 
barrier is a long study period.  A study that requires multiple visits or has a long duration will 
dissuade possible participants.  The desire to “be around” when the results are published or 
shared is very important.  There is some thought that the longer the duration of the study, the less 
likely that they will be around for it (Marcantonio et al, 2008), (Arean et al, 1996).   Other 
barriers to research, especially AD research, include caregiver stress, denial that there is a need 
for help, view that reimbursement is not worth it, multiple diseases and limited functional 
abilities, denial of vulnerability, lack of personal benefit and fear of adverse reactions (Souder et 
al, 2007).  In addition, distrust of research, lack of confidentiality, fear of safety, schedule 
conflicts, poor access to medical care, and lack of knowledge were identified by UyBico et al in 
2007.   Lastly, many older adults may not consider participating in research a worthwhile 
expenditure of energy and time when they are already burdened with multiple stressors (Arean et 
al, 2003).     
1.3.2 Race and Minority Barriers 
Race and minority status is a controversial barrier to participating in research.  While many 
studies have identified Hispanic and Black individuals with AD as an underrepresented group 
that faces many barriers to participating in research, other studies have found that belonging to 
an ethnic group was not significantly related to responding to or dropping out of research.  Arean 
and colleagues pointed out that while these studies have not found a difference in the rates of 
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participation in research among ethnic groups, the reasons for not participating, and therefore the 
recruitment and retention strategies, do differ considerably between ethnic-minority and non-
Hispanic white older adults (Arean et al, 1996).   The one issue that is well understood is that 
recruiting and retaining older minorities is much more complex than non-Hispanic whites.  The 
main barrier is centered on enthocultural beliefs, specifically beliefs of mental illness, help-
seeking behaviors, and socioeconomic status.  This barrier may manifest as fear and distrust, 
transportation issues, lack of information about the disorder, negative cultural attitudes toward 
AD and mental illness in general, and lack of knowledge about the benefits of participating 
(Marcantonio et al, 2008).  One issue that was mentioned above is the language barrier, 
especially for Hispanics and other minorities.  A significant proportion of the current Hispanic 
AD population are not fluent in English.  However, many clinical trial sites lack Spanish-
speaking staff, and many clinical trials lack materials in Spanish (Olin et al, 2002).   
Transportation issues are universal, but one specific concern is a fear of potentially becoming a 
victim of racially motivated crimes.  Therefore many older minorities may be less motivated to 
visit a center or location that is not within their neighborhood.  Care-giving is a common 
situation for many minorities and may prevent the caregivers to participate in research.   Studies 
have shown that many African American women have custody of their grandchildren and have to 
meet the needs for these children as well as care for their own needs.  These issues often resulted 
in participants’ having difficulty in coming to treatment and coming for follow-up interviews 
(Marcantonio et al, 2008).  Education or information about the disorder is not a problem that 
affects just minorities, but it is more common in this population.  Studies have found that many 
older adults are willing to participate in research studies but do not do so because they know 
little about the disorder under investigation and of the possible benefits to participating in 
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research (Marcantonio et al, 2008).  Low literacy and lack of contacts with the medical system 
contribute to low rates of participation, in addition, to delays in seeking medical attention.  
Therefore, if a family is not seeking medical attention then they will unlikely know about 
research opportunities and in many cases be excluded due to advance disease by the time 
diagnosis is made (Souder et al, 2009). Low education and cultural factors lead to misguided 
views of AD and mental illness.  For some minorities they view these disorders as a 
multidimensional condition, consisting of religious, spiritual and environmental aspects.  
Therefore, attempting to treat it in following western guidelines may appear to be degrading and 
decrease minority participation (Souder et al, 2009).  Cultural competence is one of the most 
important issues to consider when conducting research with minorities.  Research has shown that 
efforts to recruit minorities without taking into consideration cultural factors can lead to failed 
projects.  It is well known that minorities are more likely to have stereotyped ideas about mental 
health problems.  Therefore, they are less likely to participate in research.  These stereotyped 
ideas about AD and other mental illnesses lead to associated stigmas and participant burden.  
Stigma concerns of older minorities are different from their White counterparts.  Many older 
minorities are concerned with the impact a psychiatric diagnosis will have on the family’s 
reputation (Souder et al, 2009).  In addition, minorities have a tendency to view themselves as 
sicker compared to their non-Hispanic White counterparts.  This perceived level of health and 
disability significantly influences participation in research (Marcantonio et al, 2008), (Arean et 
al, 2003).    For Blacks, cultural attitudes may dictate that they cope with illnesses by taking care 
of their relative within the family and social network, instead of using the medical community.  
These beliefs also lead to a view that AD or other diseases are normal and natural occurrences 
(Souder et al, 2009).  Fear is another barrier that is not unique to minorities, but it appears 
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differently in this population.  Fear leads to mistrust of science and health services.  For various 
immigrant groups this fear stems from war related atrocities that were conducted in the name of 
science.   In Blacks, the most significant barrier to participation stems from historical events, 
such as the infamous Tuskegee Syphilis Study.  These events have lead to the perception that 
they are treated differently by medical professionals than their White counterparts due to their 
race.  Whether this is real or perceived racism, it still affects participation in research (Souder et 
al, 2009).    The recruitment of special populations requires increased resources and time to 
develop trust, knowledge of the culture, engagement of the community, and special strategies 
targeted to the particular needs of the group.  Inability to recruit a sufficient number of 
participants is a major reason for failures in clinical trials (Buckwalter, 2009). 
1.3.3 Researcher Related Barriers 
Researchers face many barriers to recruiting potential older adult AD patients as indicated above.  
Overcoming participant views, attitudes and perceptions are important, but not the only barriers 
faced when recruiting patients.  Other obstacles include health information regulations, physician 
and healthcare practitioner barriers, economic concerns and study design.  HIPAA, Health 
Insurance Portability and Accountability Act, changed the way recruitment was handled by all 
researchers.  This regulation, specifically the Privacy Rule, took effect in 2003.  This required 
researchers to gain information about patients from a “covered entity,” specifically a health care 
provider, health plan, or clearinghouse with access to the patient’s personal health information 
(PHI).  What this meant was that a health care provider had to identify potential participants and 
ask them for written permission to give the researcher their name and phone number if they want 
to learn more about a study. As a result, study recruitment is much more difficult (Sullivan-
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Bolyai et al, 2007).  Other barriers that stem from this regulation include “work burden.”  Work 
burden refers to working with busy clinicians to assist in recruitment.  It is well known that 
physicians and health care providers are extremely busy and have a large workload.  Adding an 
additional responsibility to this load can be very difficult and typically research ends up at the 
bottom of the to-do-list.  In some cases research may be viewed as extra work without 
compensation or perceived as taking time away from providing patient care (Sullivan-Bolyai et 
al, 2007).  In addition, research may be viewed as a financial disincentive if it diminishes clinic 
profit by reducing the number of patients that can be seen.   As mentioned above, physician and 
health care provider bias towards the research can impact the willingness to participate by the 
patient.  The desire to protect their patients can also restrict patients’ rights and decision making 
opportunities. A study by van Ryn and Burke (2000) found that physicians’ perceptions of 
patients may influence whether they recommend the research (Sullivan-Bolyai et al, 2007).  
These perceptions are influenced by the patients’ race and socioeconomic status. For instance, 
physicians rated patients who were African American as less compliant.  Health care providers 
may be wary if they perceive a study could physically harm or put undue stress on their patients 
(Sullivan-Bolyai et al, 2007).  Other hurdles include competing service demands on the provider, 
multicultural differences, lack of knowledge, bias against research leading to inactive 
recruitment, overly restrictive eligibility criteria, complex IRB requirements, poor relationships 
with the research team – leading to distrust of researchers and their motives, dislike of the 
research procedures (Buckwalter, 2009; UyBico et al, 2007). 
The literature illustrates that there are many barriers to conducting research in the older adult 
population, specifically the AD population.  There are many ways to overcome these barriers, 
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but they are both time consuming and expensive.  In addition, it is not always possible to 
improve participant recruitment even if obstacles have been removed.   
1.4 Chapter Summary 
In this section a detailed summary of AD was provided including current treatments.  ChEIs, the 
current symptomatic treatment, has a pharmacological interaction with other medications, 
specifically those with AC properties.  Medications with AC properties are numerous and there 
is much evidence that they cause negative outcomes in older adults.  There is also some evidence 
that they may cause negative outcomes in dementia patients.  Additionally, the idea of AC 
burden, the cumulative effect of the total AC medications that a person consumes, was 
introduced and measurements of this burden described.  While research in this area is constantly 
increasing, most of the studies are observational.  While a randomized controlled study would 
provide important evidence as to the causal relationship, recruitment issues are a considerable 
barrier to performing this type of research.  Therefore the last section discusses the several 
barriers that are involved including universal, race/minority and researcher related ones.  These 
barriers once taken into consideration and overcome will enable stronger studies to occur. In 
Chapter 3 the preliminary research that has been conducted will be discussed.  Two preliminary 
projects are discussed, one that was completed and the other that was stopped due to low patient 
recruitment.  In Chapter 4, the methodologies for a retrospective database project conducted at 
Piedmont Geriatric Hospital are described.  Finally the results and the discussion are presented in 
Chapters 5 and 6, respectively.  
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Chapter 2 
Significance and Specific Aims 
 
2.0 Significance  
AD and dementia in general are incurable diseases with no disease modifying treatments 
available.  As the disease progresses, great medical and social changes occur.  The cognitive 
deficits that develop limit patients’ ability to understand written information and participate in 
consequential conversation. The limited social activities due to deficits in function may increase 
the risk of illnesses and poor health that may trigger negative behaviors and increase medication 
uses.  Additionally, there are negative changes in behavior caused by the inability to articulate 
discomforts or frustration.  Behavioral problems can increase the risk of receiving harmful 
medications (Forchetti, 2005).  Working with moderate to severe dementia patients can be 
difficult, which may be one reason why there is little research in this population.   
While most families prefer to keep their loved ones at home for as long as possible, many 
moderate to severe dementia patients live in long-term care facilities or hospitals.  A 2008 study 
found that 68% of all nursing home residents had some degree of cognitive impairment 
(Alzheimer’s Association 2010).  Additionally, 41% of those older adults had moderate to severe 
impairment (Alzheimer’s Association 2010).   Therefore it is important to study dementia 
patients in institutionalized care. 
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The current standard of care with the use of cholinesterase inhibitors (ChEIs) and memantine, is 
very expensive and provides only modest improvements. Only ChEIs have an indication for mild 
disease, but both ChEIs and memantine have indications for moderate and late disease.  While 
there are some studies that suggest positive outcomes from the use of these medications in late 
disease, there are also studies that show no significant outcomes (Forchetti, 2005). Furthermore, 
research has shown that receiving a cholinesterase inhibitor increases the likelihood of being 
prescribed an AC medication (Gill et al 2005; Robinson et al, 2009).  Moreover, the concurrent 
use of the two classes of medications is not an uncommon occurrence (Feinberg, 1993).  This 
combined use may reduce the benefit of the ChEIs as these two classes have opposing 
pharmacological mechanisms of action.  There are epidemiological studies that show that 
concurrent use of these two classes has the potential to cause harm to AD patients (Han et al, 
2008).  The ChEI approval trials excluded AD patients taking AC drugs; therefore there is no 
evidence to support the concurrent use of these two classes of medications as part of FDA-
regulated drug development.   
Time is also a significant factor in dementia.  Each dementia patient is different in how they 
progress through the disease.  Some progress more rapidly than others and some have more 
behavioral or functional problems than others.  By collecting data over a period of time, one is 
able to better understand and correlate the effects of medications and other factors on health and 
social outcomes. Therefore, research in dementia patients should consider change over time 
rather than a single point in time (Twisk, 2003). 
This study is based on the hypothesis that drugs with AC effects impair function, memory, and 
behavior in dementia patients. Furthermore, the concurrent use of AC drugs with ChEIs impairs 
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the efficacy of drug therapy in patients taking ChEIs.    While most studies focus on the 
cognitive effects of AC burden and concurrent use, few investigate functional and behavioral 
outcomes.  It is believed that AC effects on dementia may lead to a faster decline in cognition, 
function, and behavior based on the evidence from the use in psychiatrically stable older adults 
(Tune et al, 1992)   It is expected that this decline will be seen in the patients taking ChEIs as 
they are more likely to receive an AC drug and subsequently higher anticholinergic burden that 
would counteract the effects of ChEIs.  Hence, the greater the burden it is expected the greater 
the decline in function, cognition, and behavior over time.   
2.1 Specific Aims 
The specific aims of this study are: 
o To quantify anticholinergic burden in moderate to severe dementia patients 
receiving long term treatment in a state geriatric psychiatric hospital. 
o To assess the function in dementia patients with varying anticholinergic burdens 
due to their concurrent medications. 
o To assess the cognition and behavior in dementia patients with varying 
anticholinergic burdens due to their concurrent medications. 
o To identify anticholinergic medication- and patient-related factors relevant to 
functional outcomes in dementia patients taking anticholinergic drugs. 
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Chapter 3 
Preliminary Research 
 
3.0 Chapter Introduction 
In this chapter two preliminary studies investigating AC use will be discussed.  The first study is 
a retrospective analysis of the University Health-System Consortium database, investigating the 
prevalence of AC drug use in older adult inpatients without dementia.  This study is still 
ongoing, therefore only preliminary results are provided.  The second study was a prospective 
analysis of functional, behavioral, and cognitive functioning in older adults with mild to 
moderate AD.  This study was stopped prematurely due to the difficulties in recruitment of study 
participants.   
3.1 Anticholinergic Drug Use in the Hospitalized Elderly 
3.1.1 Background and Significance 
AC medications inhibit or block the actions of acetylcholine in both the peripheral and the 
central nervous system.  Wide varieties of medications possess AC properties and are frequently 
prescribed for health conditions common in the elderly.  The medications can have a cumulative 
effect that may cause early cognitive declines (Kay et al, 2004).  Older adults are vulnerable 
because of the decrease in effectiveness of the blood-brain barrier, changes in body composition  
and altered drug elimination pathways. 
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This in conjunction with reductions in metabolism and elimination increase the risk for adverse 
AC effects.  The central nervous system dysfunction is shown by changes in memory, disruption 
of sleep, hallucinations, confusion and delirium that could lead to an increase in hospital stay 
(Kay et al, 2004). 
The specific aims of this project were to study the prevalence of AC drug use in non-demented 
elderly inpatient population, to observe the most commonly used AC medications and to study 
the relationship between length of stay and AC burden. Based on the available evidence we 
hypothesized that the prevalence of AC drug use was common and that those patients taking 
these medications would have a longer length of stay.   
3.1.2 Methods 
3.1.2.1 Data Source 
The data was obtained from the University Health-System Consortium (UHC) Clinical Database 
(CDB), which is an alliance of 90 academic health centers in the United States.  The UHC CDB-
Pharmacy database contains procedure and diagnosis-specific data from discharge abstract 
summaries, Universal Billing Code of 1992 (UB-92), and medication use data from charge 
transaction masters and patient billing files for all inpatients at participating centers.  The UB-92 
is a standardized database used by hospitals to generate itemized charges for patient visits.  One 
year of data was evaluated from October 2003 to September 2004.  This study was reviewed by 
the Virginia Commonwealth University (VCU) Office of Research Subject Protection 
Institutional Review Board (IRB) and found to qualify for exemption from federal regulations 
requiring IRB review and approval. The study population included hospitalized patients 65 years 
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of age or older with no evidence of dementia.  Evidence for dementia included ICD-9 codes for 
any type of dementia illness or receiving a ChEI. 
3.1.2.2 Data Collection 
Several variables were collected from the database including the medications that a patient was 
receiving, age, sex, race, observed hospital length of stay (LOS), AC drugs, severity score 
(evaluation of severity of illness and risk of mortality), whether they were discharged to a 
nursing home and the presence of delirium based on ICD-9 codes.   The ICD-9 codes included 
292.81 (drug-induced delirium), 293.0 (acute delirium) and 293.1 (subacute delirium).   
Calculated variables included AC medication use, AC burden, and AC potency.  The outcome 
variable, LOS, was not normally distributed and was log-transformed.  AC medication use was 
coded as yes/no and was determined for each patient in each group. The AC medications with 
CNS activity included in this review are listed in Table 4. Combination drug products containing 
one of these ACH drugs were also evaluated.  For each AC medication, AC burden was 
determined using the following equation: dose [high, med, low] x days of therapy x ACH 
potency [high, med, low].  These classifications as high, medium or low were based on clinical 
judgment (by a geriatric pharmacist and researcher) and dosing recommendations for the elderly 
obtained from Lexi-Comp®.  The resulting values were summed across all AC drugs.   AC 
potency was estimated based on published in vivo and in vitro data available in the published 
literature, Lexi-Comp and clinical judgment.  
There were potential confounding variables including discharge status, race, sex, age, delirium, 
and severity score.  Discharge status was coded as “yes” = 2 if discharged to a skilled nursing 
facility, rehabilitation center, psychiatric center, long-term care hospital, intermediate care 
 44 
 
facility, federal hospital, acute care facility, or hospice/medical facility, otherwise it was coded 
as “no” = 1.  Race was coded as “White” = 1, “Black” = 2, and “Asian”, “Hispanic”, “North 
American Indian/Eskimo” or “other” = 3.  Sex was coded as “male” = 1 and “female” = 2.  
Delirium was coded as “yes” = 2 and “no” = 1.   The UHC database accounts for severity of 
illness and comorbid conditions (CCS) variables using a combination of the Diagnosis-Related 
Groups (DRGs) and the UHC Complication Profiler (UCP) (UHC, 2008).  Four levels of severity 
are defined: as baseline (no substantial CCS), moderate CCS, major CCS, and catastrophic CCS 
(surgery).    
3.1.2.3 Data Analysis 
The prevalence of centrally acting AC drug use was calculated by dividing the number of 
patients taking the drugs by the total number of patients in the non-demented group.  The 
percentage use for each drug was calculated by dividing the number of courses of therapy for 
that drug by the total number of courses of therapy for all AC drugs. Average daily dose and 
average days of therapy for each of the centrally-acting AC drugs was also calculated.  
Stepwise multiple linear regression was used to assess the relationship between LOS and the 
independent variables. LOS was log transformed for this analysis.  The independent variables 
evaluated were standardized scores for age, race, sex, severity score, discharge status, whether or 
not delirium was documented, and whether or not the patient received an AC drug.  Furthermore, 
this technique was also used to determine the relationship between LOS and AC burden in those 
patients who received at least one AC medication. This was performed to evaluate whether 
higher AC burden is associated with longer LOS in patients without dementia.  Again the 
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dependent variable was log transformed LOS and the independent variables included were age, 
sex, race, severity score, discharge status, delirium diagnosis, and AC burden score.  
3.1.3 Results 
The results included in this section are preliminary as the study analysis is still continuing.  
There were a total of 210,103 inpatients in the dataset without dementia; of this group 37.8% or 
79,493 were taking one of the medications listed in Table 4.  The patient demographics are 
shown in Table 5.  The average dose per day, average days of therapy, and frequency of the most 
commonly prescribed AC medications are shown in Table 6.  
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Table 4: Centrally Acting Drugs with AC Properties 
 
TCA/ TCA Combinations Antispasmodics 
Amitriptyline Atropine 
Amitriptyline/chlordiazepoxide Belladonna alkaloids 
Amitriptyline/perphenazine Belladonna L-alkaloids 
Desipramine Dicyclomine 
Doxepin Dicyclomine/phenobarbital 
Imipramine Hyoscyamine 
Nortriptyline Scopolamine 
Antiparkinson Agents Urinary Antispasmodics 
Benztropine Oxybutynin 
Trihexyphenidyl Tolterodine 
Antipsychotics Antihistamines 
Chlorpromazine Diphenhydramine 
Clozapine Hydroxyzine 
Olanzapine Promethazine 
Promazine  
Thioridazine  
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Table 5: Patient Demographics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age (yrs), mean ±SD 75 ±7.3 
Females 52.8% 
Racial Distribution:  
White 69.7% 
Black 14.6% 
Hispanic 3.7% 
Asian 1.6% 
Other or unknown 10.4% 
Severity Score:  
Baseline (no CCs) 23.3% 
Moderate CCs 38.6% 
Major CCs 27.8% 
Catastrophic CCs 9.5% 
Unknown 0.7% 
Discharge to an institutional setting 20.6% 
Documented delirium 1.2% 
Median LOS (days) 4.0 
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Table 6: Most Commonly used AC Drugs in the Hospitalized Elderly  
Drug Frequency 
(%) 
Average 
dose/day 
(mg) 
Average 
days of 
therapy 
Diphenhydramine  46 46.5 1.8 
Promethazine  22.2 34 1.8 
Atropine  9.1 1.6 1.1 
Olanzapine  3.8 8.7 4.8 
Oxybutynin  3.5 10.2 4.5 
 
For the stepwise regression only 68,697 inpatients from the dataset were included.  This was the 
total number of inpatients that were taking at least one AC drug and had a complete data set.  
The regression found that severity score, discharge status and whether or not the patient received 
an AC drug were the most statistically significant predictors of LOS with an r2 of 0.29.  The 
model accounts for 29% of the variability in the LOS.  AC burden was determined to be 
statistically significant in relation to length of stay, with only the severity score and discharge 
status as more significant, respectively.  The r2
3.1.4 Discussion 
 value was 0.326 and this demonstrated that the 
higher the AC burden for an elderly inpatient, the longer their hospital stays.    
AC medication administration is common in older adults especially in a hospitalized setting. 
Approximately one third of the inpatients without dementia in this study were on an AC 
medication.  Previous studies have shown a link between the use of diphenhydramine, an AC 
medication, and an increase in length of hospital stay as a result of an adverse drug event 
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(Agostini et al, 2001).  This study demonstrated the same result indicating that intervention 
should be evaluated to prevent this outcome.   
 
AC burden is defined by Kay et al as the cumulative effect of taking multiple medications with 
AC activity (Kay et al, 2004).  There are different ways to determine this burden, one method is 
developing an equation as was done in this study.  The equation for AC burden was developed 
by using the Geriatric Dosage Handbook as a reference in assigning high, medium or low doses 
and in determining potency. This approach was used because this is a retrospective study and 
blood samples were not available to run a radio receptor assay.  The equation method is an 
estimate as a true value cannot be determined because each individual’s pharmacokinetics is 
different.  Therefore, further studies are needed to validate the equation.  Other limitations of the 
study include the observational and retrospective nature of the study design, which limits the 
ability to draw conclusions about causality in the association between AC drug use and hospital 
LOS.  In addition, the data was collected from hospital data generated for reimbursement 
purposes and not for the specific purposes of this study.  This limits the kind of information and 
the level of detail available for the study.  Also, the potential to cause different AC side effects is 
different for each drug depending on blood brain barrier penetration and muscarinic receptor 
subtype affinity.  Effects were assumed to be additive when they may be synergistic.  Drugs with 
low potential for AC side effects were not evaluated, but these drugs may contribute to a 
cumulative AC effect. Furthermore, delirium appeared to be poorly documented in this dataset, 
making it difficult to evaluate as a contributor to hospital LOS. 
3.2 Cognitive, Functional and Behavioral Outcomes Associated with Anticholinergic Drug 
Use in Alzheimer's Disease Patients Taking Cholinesterase Inhibitors 
3.2.1 Background and Significance 
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Many different types of medications possess AC properties.  These medications can be divided 
into two groups, those that are used therapeutically for their AC effects and those that do not 
derive their therapeutic benefit by blocking acetylcholine receptors, but have AC side effects.  
The first are used to treat clinical disorders frequently comorbid with AD including Parkinson’s 
disease and urinary incontinence.  Additionally, some may be prescribed to treat the side effects 
of cholinesterase inhibitor therapy (Hashimoto et al, 2000; Gill et al, 2005).   
A number of studies have reported on the adverse effects associated with AC drugs in general 
elderly populations. A few studies have found elderly to be at risk of cognitive impairment even 
at low serum AC levels (Mulsant et al, 2003).  Impairment of self-care capacity and cognition 
have also been found to be associated with high serum AC levels in dementia nursing home 
patients (Rovner et al , 1988).  AD patients are at risk of additional impairment from AC drug 
therapy (Theinhaus et al, 1990).  There is little data from clinical studies documenting the 
effects of concurrent AC and acetylcholinesterase inhibitor therapy on the cognition, function 
and behavior in AD patients.  This group is expected to be at even greater risk for adverse 
effects of AC drugs due to age and disease-related changes.  Surveys of administrative claims 
data from different state Medicaid plans have found that patients receiving cholinesterase 
inhibitors were also receiving AC drugs with significant central activity during a 3-month 
period (Slattum et al, 2001; Carnahan et al, 2006). In a retrospective study of 69 patients with 
AD taking donepezil, 16 received concurrent AC medications and experienced a significant 
decline in cognitive function over two years compared to patients with no concurrent AC 
medications (Lu et al, 2003).  A follow-up to this study provides preliminary data that shows a 
non-significant decline in physical activities of daily living and instrumental activities of daily 
living (Bottiggi et al, 2006). 
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The hypothesis that guided this research was that the administration of AC drugs impairs 
memory, function, behavior and drug therapy efficacy in AD patients taking cholinesterase 
inhibitors.  The specific aims for this project included assessing the changes in cognition, 
function, and behavior over time in AD patients taking cholinesterase inhibitors and drugs with 
AC properties.  Additionally, to identify AC medication- and patient-related factors relevant to 
cognitive, functional, and behavioral outcomes in this population.   
3.2.2 Methods Introduction  
This study was modified several times in an attempt to address barriers of feasibility and 
recruitment.  The original study was an intervention using three local physicians.  The physicians 
were unable to participate for various reasons, and the study was changed to an observational 
design.  The initial observational study required a blood draw in order to use SAA to quantify 
AC burden.  The participants would still have had three visits, but they were required to have 
their visits at Medical College of Virginia (MCV) in order for the blood to be drawn.   
Participants were unwilling to come to the downtown academic medical center due to the traffic 
and nature of a hospital setting.  This prompted a change to find another method of calculating 
burden without a blood draw to enable patients to be seen at a preferred location such as their 
home.  The study was changed to use a scale, specifically the Anticholinergic Drug Scale, as a 
method of burden quantification.  The main reason for the many changes to this study design was 
difficulty in patient recruitment.  
3.2.2.1 Study Design 
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This observational study was conducted in participants with probable AD taking a ChEI in 
addition to either a low AC burden or a high AC burden.  The total number of participants 
needed was 90 with 45 in each of the two AC groups.  Selected participants underwent three 
assessments of cognition, function and behavior, three months apart in order to determine the 
rate of decline in outcome measures.  These assessments were performed by a blinded student 
investigator and a graduate student.   Demographic data including age, sex, residence, years of 
education, current diagnoses, duration of AC drug use, time since AD diagnosis, current AC 
dosing regimen, current dosing regimen of acetylcholinesterase inhibitor, indication for AC 
medication, other concurrent medications, and perceived effectiveness of AC and cholinesterase 
inhibitor medications were obtained on the Patient Intake Form (Appendix A).  Furthermore, 
demographic data for the caregiver was collected using the Caregiver Intake Form (Appendix B).   
Quantification of AC activity resulting from the various AC medications taken by the 
participants was determined using the AC Drug Scale (ADS).  An acetylcholinesterase 
equivalent dosing chart was used as a means of normalizing cholinesterase inhibitor exposure.  
3.2.2.2 Participants  
Participants were eligible for inclusion in the study if they had a diagnosis of probably AD based 
on medical history, mental status evaluation, clinical examination, or other tests as outlined in 
the Differential Diagnosis of AD Algorithm from the Alzheimer's Association 
(www.alz.org/Health/Diagnose/procedure.asp).  Diagnosis was confirmed by the referring 
physician or the patient’s primary care physician with authorization from the legally authorized 
representative.  Participants were required to have a Mini-Mental State Examination score of 16 
to 24, which corresponds to mild to moderate disease.   In addition, participants had to be taking 
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a ChEI chronically.  All of the currently available ChEIs were included, tacrine, donepezil, 
rivastigmine and galantamine.  Chronic use of a medication was defined as daily use for greater 
than 30 days.  Additionally, participants had to be medically stable without evidence of acute 
medical or psychiatric illness.  Furthermore, they were excluded if they had problems with visual 
acuity, hearing or motor disturbances that were severe enough to prevent completion of testing 
procedures.  Potential participants were also required to have a representative that was able to 
provide written informed consent to participate in the study.  The participant themselves were 
required to provide assent to participate.   In addition, a knowledgeable caregiver who was able 
to participate in the outcome measurements was required. A knowledgeable caregiver is defined 
as the primary person in charge of caring for an individual with Alzheimer’s disease, usually a 
family member or a designated health care professional.   If the potential participant was residing 
in a home or facility they were required to have a caregiver present.  Selected participants were 
assessed at the location of their choice or at the VCU General Clinical Research Center.   
Group 1 participants were taking at least one centrally-acting AC drug chronically.  AC drugs 
were defined as one of the following: tricyclic antidepressants (amitriptyline, doxepin, 
imipramine, desipramine, nortriptyline), sedating antihistamines (diphenhydramine, 
hydroxyzine, promethazine), antiparkinson’s drugs (benztropine, trihexyphenidyl, biperiden, 
procyclidine), urinary antispasmodics (oxybutynin, tolterodine, darifenacin, propantheline, 
solifenacin), gastrointestinal antispasmodics (atropine, scopolamine, hyoscyamine, belladonna 
alkaloids, dicyclomine), and antipsychotics (chlorpromazine, clozapine, promazine, thioridazine, 
olanzapine).  Group 2 participants were taking no centrally acting AC drugs from the list above 
on a chronic basis. 
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Potential participants were recruited through physicians who treat Alzheimer’s patients in the 
Greater Richmond area.  Physicians were provided with the study protocol and advertisements. 
Advertisements were shared with prospective volunteers who contacted the PI if they were 
interested in screening for the study.  Participants were also recruited through the Alzheimer’s 
Association, Greater Richmond Chapter and the Commonwealth of Virginia Alzheimer’s 
Commission.  The Alzheimer’s Association was provided with advertisements that could be 
included in the association newsletter, distributed at support groups and conferences, and other 
venues.  Also, advertisements were placed in Senior Living magazine and other organizations in 
the senior network.  The referring physicians, the Alzheimer’s Association and other 
organizations did not provide names or contact information of potential participants directly to 
the PI.   
The PI or co-investigator conducted the informed consent and assent processes with the 
participant and their representative.  The participant and their representative received a copy of 
the consent form, reviewed it with the PI or co-investigator, and had an opportunity to discuss it 
with the PI or co-investigator.  Consent was documented in writing. 
3.2.2.3 Outcome Measures 
Outcome measures were collected during three study visits three months apart with the 
participant and their knowledgeable caregiver.  Assessments were made by the student 
investigator and a graduate student.  Both were fully trained by an experienced psychologist (Dr. 
Ayn Welleford, Department of Gerontology, VCU) to administer all of the outcome assessments. 
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To avoid potential bias, each participant was de-identified using a number.   Participants were 
offered a rest break between measurements.   
3.2.2.3.1 Assessments  
The specific outcome measures used in this study included the cognitive measures of 
Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and the Mini-Mental 
State Examination (MMSE) with clock drawing.  Functional outcomes included the Physical 
Self-Maintenance Scale (PSMS) and behavioral outcomes were assessed using the 
Neuropsychiatric Inventory (NPI).  The last outcome measured was delirium using the Delirium 
Rating Scale-Revised-98. 
 
The ADAS-Cog was the primary assessment of cognition.  It is an 11-item test that measures the 
disturbances of memory, language, praxis, attention and other cognitive abilities which are often 
referred to as the core symptoms of AD with a score ranging from 0 to 70 with higher scores 
corresponding to more impairment.  This test was used in the anti-dementia trials and is 
considered the gold-standard.  Cross-sectional and longitudinal studies have shown that the total 
score on the ADAS-cog correlates with disease severity (Sevigny et al, 2010).  Moreover, studies 
have shown that the ADAS-cog has high sensitivity and specificity for evaluating disease 
severity (Pera-Casanova, 1997).   
The second cognitive assessment tool was the MMSE with clock drawing, which was performed 
to facilitate comparison of the results with other studies. This test is a simple and brief standard 
mental status exam routinely used to measure a person’s basic cognitive skills.  This 11-item 
instrument evaluates several cognitive domains such as short-term memory, long-term memory, 
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orientation, registration, attention, visual construction skills and language. Scores range from 0 to 
30, with higher scores corresponding to less impairment.  The MMSE has sensitivity (87%) and 
specificity (82%) in the identification of dementia (Rosselli et al, 2006). 
 
The PSMS, the functional instrument, is a brief assessment of the activities of daily living, 
specifically the ability to perform self-care, self-maintenance and physical activities.  It is a six-
item scale that rates self-care ability in toileting, feeding, dressing, personal hygiene and 
grooming, locomotion (physical ambulation), and bathing.  It is based on the information 
provided by caregivers.   For each activity, the patient is rated from 1 (independence) to 5 
(dependence), hence higher scores are indicative of more impairment (Lawton et al, 1969).  
Behavior was assessed using the NPI, a tool that evaluates 10 disturbances associated with 
dementia.  These include delusions, hallucinations, dysphoria, anxiety, agitation/aggression, 
euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity.  There are two 
additional behaviors that are assessed including night-time behavior disturbances, and appetite 
and eating abnormalities.  The NPI measures both frequency and severity of each behavior.  This 
assessment also uses caregiver input to assess these disturbances.  A high score on this 
instrument is associated with greater impairment (Cummings et al, 1994).   
The last assessment used in this study was the Delirium Rating Scale-Revised-98, a tool to 
evaluate delirium in the dementia participant.  This is a validated, 16-item clinician-rated scale 
with 13 severity items and 3 diagnostic items, maximum total scale score of 46 points (includes 
the three diagnostic items) and a maximum severity score of 39 points (Trzepacz et al, 2001).  It 
is not uncommon for older adults to suffer from drug-induced delirium with AC medications, 
especially in those with dementia (Gareri et al, 2007). 
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3.2.2.3.2 AC Burden Quantification 
The ADS was used to calculate AC burden in the participant at each visit.  This was done by 
obtaining a full list of medications from the participant.  The ADS quantifies the AC potency of 
each medication based on ratings.  Each medication, both chronic and as needed, was rated on a 
level of 0 to 3.  Level 0 medications have no known AC properties; level 1 medications are 
potentially AC based on receptor binding studies; level 2 medications have been shown to cause 
AC adverse events at excessive doses; and level 3 medications are known to be markedly AC.  A 
list of medications that are rated as 0 to 3 is provided in Appendix B (Carnahan et al, 2006).  The 
ratings were then added together to determine the ADS total score.  If a medication is used as 
both a scheduled and as needed medication then its rating is added twice. 
3.2.2.3.3 ChEI Categorization  
A ChEI dosing table was used to categorize the dose as initial, middle or maximal since the 
medications have been shown to have similar efficacy (Wilkinson et al, 2002; Liston et al 2004). 
The initial dose of donepezil is 5 mg and the maximal dose is 10 mg. The initial dose of 
rivastigmine is 3 mg, the middle dose is 6 mg to 9 mg and the maximal dose is 12 mg. The initial 
dose of the rivastigmine patch is 9 mg and the maximal is 18 mg.  The initial dose of 
galantamine immediate release and extended release is 8 mg, the middle dose is 16 mg and the 
maximal dose is 24 mg.   
 
3.2.2.4 Statistical Analysis  
3.2.2.4.1 Sample Size  
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The calculation of the number of required participants for this study was based on a study 
conducted in non-demented and probable Alzheimer’s patients where SAA was correlated with 
cognitive performance with r = 0.29 (Theinhaus et al, 1990).  The sample size necessary to detect 
a similar correlation in our study (α = 0.05, β = 0.20, for a one-sided test) is 67.  A second basis 
for the sample size was a t-test comparison of low and high AC burden patients.  It was assumed 
that patients with mild to moderate AD with high AC burden will behave as patients receiving a 
placebo rather than a ChEI. Data on change from baseline in ADAS-cog score for placebo 
treated and optimally treated patients can be used to estimate sample size.  In a study of patients 
with mild to moderated AD, the weighted mean difference in change in ADAS-cog score over 
six months for placebo and donepezil treated patients was 2.92 with equal SD of 5.5 (Birks J, 
2006).  The sample size necessary to detect a similar difference (α = 0.05, β = 0.20, for a one-
sided test) is 45 per group. 
3.2.2.4.2 Analysis Plan 
The change over 6 months for each clinical outcome was to be compared for Groups 1 and 2 
using a one-sided t-test (α = 0.05).  If assumptions of the t-test were not met, data transformation 
and alternative approaches would be explored.   This analysis assumes that participants would 
remain in the high or low burden group throughout the six month study period.  After the first 20 
participants completed the study, the validity of this assumption was to be assessed.  Based on 
the results of the first 20 participants, the study analysis plan might have been adjusted.  
Additionally, in the case that an alternative plan was needed the data collected at the 3-month 
assessment could have been used in the analysis.   
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The relationship between each clinical outcome and anticholinergic activity at each visit was to 
be evaluated using multiple regression. Demographic variables (patient and therapy-related 
factors) and cholinesterase inhibitor dose category would be included as dependent variables in 
each analysis.  Statistical analyses were to be performed using SPSS Version 16.0 for Windows. 
3.2.3 Results  
The study was closed in the Spring of 2010 due to low enrollment.  During the two years that the 
study was open there were three participants that completed all three study visits.  There were 
two more participants who were unable to maintain the minimum MMSE requirement at the first 
visit.  Subject 4 was unable to finish the assessments due to aggression and agitation.  It was 
determined that she would be unable to continue the study due to the progression of her disease.  
Subject 5 was cooperative, but had a MMSE score of 12/30 following the first meeting.  This fell 
below the 16/30 minimum requirement.   
Of the three participants that completed the study, one had high AC burden and the other two fell 
into the low AC burden group.  The demographics are shown in Table 7.  For all three 
participants there was no change in the AC medications or in the ChEIs and NMDA receptor 
antagonists that they were taking over the six month time period.  All three participants were 
taking donepezil and two of the three were taking memantine.  The average age of the 
participants was 71.7 ± 12.0.  As shown in Appendix A, there were several domains collected on 
each participant, but the questionnaire was incomplete for some of the participants.  Hence only 
the variables listed in Table 7 were complete for all participants.   
Table 7: Demographics 
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  Subject 1 Subject 2 Subject 3 
Age 84 71 60 
Sex Female Male Male 
Marital 
Status Married Married* Married 
Ethnicity White Black White 
Residence ALF Home Home 
Education 16 12 20 
Smoking No No No 
* Widowed after 2nd 
The summary of the outcomes for each participant is located in Table 8.  As shown in Table 8, 
Participant 1 has the highest ADS score that corresponds to the lowest MMSE and ADAS-cog 
scores.  Participant 1 was taking solifenacin which is known to be markedly AC based on SAA 
studies.  The NPI scores did not conform to the trend that was seen between ADS scores and 
cognition as well as function. Regression analyses were not performed due to the small sample 
size.    
visit 
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Table 8:  Summary of Outcome Measures 
  Visit 1 Visit 2 Visit 3 Average ± Std Dev 
  Subject 1 Subject 2 Subject 3 Subject 1 Subject 2 Subject 3 Subject 1 Subject 2 Subject 3 Subject 1 Subject 2 Subject 3 
ADAS-cog 29.0 18.0 25.0 26.0 16.0 26.0 41.0 20.0 30.0 32.0 ± 7.93 18.0 ± 2.00  27.0 ± 2.65 
MMSE 17.0 24.0 20.0 19.0 24.0 20.0 17.0 24.0 21.0 17.7 ± 1.15 24.0 20.3 ± 0.58 
Delirium 13.0 6.0 9.0 15.0 7.0 11.0 14.0 5.0 13.0 14.0 ± 1.00 6.0 ± 1.00 11.0 ± 2.00 
NPI 3.0 11.0 38.0 3.0 10.0 29.0 3.0 0.0 28.0 3.0 7.0 ± 6.08 31.7 ± 5.51 
Caregiver 
Occupational 
Distress 
(NPI) 2.0 9.0 14.0 2.0 5.0 13.0 2.0 0.0 8.0 2.0 4.7 ± 4.51 11.7 ± 3.21 
PSMS 11.0 9.0 6.0 13.0 9.0 8.0 13.0 6.0 8.0 12.3 ± 1.15 8.0 ± 1.73  7.3 ± 1.15 
ADS 3.0 0.0 0.0 3.0 0.0 0.0 3.0 0.0 0.0 3.0 0.0 0.0 
ChE Maximal Initial Maximal Maximal Initial Maximal Maximal Initial Maximal Maximal Initial Maximal 
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3.2.4 Discussion 
The lack of participants accounted for the premature termination of the study.  Much time was 
spent on advertising to caregivers and healthcare workers to no avail.  The three participants 
were recruited by means of different avenues. Participant 1’s caregiver contacted the PI about the 
study, while Participant 2 was recruited by their physician and Participant 3 by the local 
Alzheimer’s Association chapter.   There were barriers that were faced in recruitment of 
participants.  Many of the barriers were legal in nature with the nursing homes, assisted living 
facilities, and adult day centers.  These facilities required approval from the power of attorneys 
(POAs) or family members in order for the patients or residents participate.  In addition, many of 
these facilities were not willing to send a letter with the advertisement to the families and POAs.  
For the few adult day centers interested in participating, there was either a lack of interest among 
the families/POAs or the patient did not meet the requirements to participate.  One assisted living 
facility that also had an independent living section, allowed for the advertisement to be posted in 
the pharmacy.  This was the advertisement that Participant 1’s husband saw.  As discussed 
previously, spousal and family support was a significant barrier to participating in research 
studies.  The study by Marcantonio et al. in 2008 found that approximately 55% of potential 
participants indicated that they would decline if their spouse was not interested or did not 
approve of the research (Marcantonio et al, 2008).   
Another barrier that was faced was associated with physician support.  Physicians from the 
Alzheimer’s Association referral list of doctors who treat AD patients were contacted and asked 
to facilitate patient recruitment.  Many physicians chose not to participate in either providing a 
flyer to the possible participant or posting the flyer in their office or practice site.  This may be 
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due to the perceived additional work that is involved in assisting to recruit patients.  Additional 
barriers may have been bias towards research or lack of belief in the importance of the research 
question (Sullivan-Bolyai et al, 2007).    
One additional barrier may have been perceived benefit.  AD is an irreversible disease that leads 
to significant loss of quality of life.  This study was not a treatment study and therefore may have 
been considered a less worthwhile project to participate in.   
There was a great deal of variability between the three participants that may have contributed to 
their cognitive, behavioral and functional scores. Participant 1’s caregiver was her husband yet 
did not live with her in her apartment unlike the other two.  Furthermore, she had a twin who had 
passed away from AD.  Participant 2’s third visit NPI and PSMS scores were based on 
information provided by the daughter who did not live with him.  His wife had passed away not 
long before the third visit.  This is likely why the NPI and the Caregiver Occupational Distress 
scores were significantly less than the previous visits.  Participant 3’s caregiver was the only one 
who worked outside the home and had younger children.     This explains in part the significantly 
higher NPI and Caregiver Occupational Distress scores.  These factors make any generalizations 
impossible as does the small sample size.  
The student investigator was present at all visits and performed all cognitive and delirium 
assessments.  The additional graduate student was present at all 3 of Participant 1 and 2’s visits.  
Also, she completed the PSMS and NPI with the caregivers for these two subjects.  Therefore, 
inter-rater reliability was high.   
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In conclusion, this study had the potential to provide valuable evidence as to whether AC burden 
has a negative effect on cognition, function, and behavior in AD patients.  Due to the multiple 
barriers associated with recruiting participants this study was terminated.  Further research in this 
area is necessary as the pharmacological potential for negative consequences of AC burden in 
AD may not translate to clinical adverse events.  Moreover, further research is needed in 
overcoming barriers associated with AD patient and caregiver participation.  This will provide 
for greater participation in important studies that may improve the quality of life patients and 
their caregivers.   
3.3 Chapter Summary 
This chapter described two preliminary research studies.  The first is still ongoing, but the initial 
findings support other research with respect to the prevalence of 33% and the increased LOS 
associated with use of AC medications.  As shown in Table 2 from Chapter 1, within the last 30 
years the prevalence has ranged from as low as 6% to as high as 80%.   The majority of the 
studies found that the range was about 20%-30%.  Additionally, the study by Agostini et al, 
found that length of stay was increased with the use of diphenhydramine.  The results from the 
second study are inconclusive with so few participants.  With growing evidence for the high 
prevalence of AC medications and the negative effects associated with their use in older adults, it 
is imperative that more research be conducted in dementia patients using these medications.  The 
second study had the potential to evaluate the use of AC medications on dementia patients, but 
due to recruitment barriers, this was not completed.  The next option is to perform a retrospective 
analysis of dementia patients, which is the basis for the study discussed in the next chapters.   
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Chapter 4 
Methods 
4.0 Chapter Introduction 
This chapter describes the methods for a retrospective, longitudinal study that was conducted 
using data from patient charts for dementia patients receiving care at Piedmont Geriatric 
Hospital.  This study was derived from the prospective preliminary study discussed in the 
previous chapter.  Hence the same outcomes of function, behavior and cognition were evaluated, 
but through different assessments.  Additionally, the objective of evaluating the association 
between AC burden and functional, behavioral and cognitive outcomes was the same as the 
preliminary study.  The patients were identified by the hospital and then charts were reviewed to 
obtain the demographic, pharmacy and outcome information.  This data was compiled and then 
statistical analysis was preformed to identify any associations between the outcomes and AC 
burden.  The process is described in detail below.   
4.1 Effect of Anticholinergic Burden on Functional Outcomes in Patients with Dementia 
4.1.1 Study Design 
The study was a retrospective observational study of moderate to severe dementia patients at a 
state geriatric facility.  Both the VCU Institutional Review Board (IRB) and Piedmont Geriatric  
Hospital (PGH) IRB approved the study protocol. 
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 PGH is Virginia’s only state facility exclusively for older adults aged 65 and over with mental 
illness.  It is a 135-bed hospital located in rural Burkeville, VA.  Typically only about 122 to 128 
beds are filled at any given time.  The patient length of stay varies from a few days to several 
years depending on the severity of the patient’s condition (Piedmont Geriatric Hospital, 2010).    
The hospital requires that authorization be received to use any chart information, including non-
personal health information (PHI).  A letter was used as informed consent and sent out to the 
family and representatives for the patients’ who were still living.  This letter is included in 
Appendix C.  The families and representatives were given two weeks to decline interest.  A non-
response was deemed as an agreement to be included in the study.   
Charts dated from 2000 to the present were reviewed to obtain the monthly nursing reports.  Data 
from the reports were recorded for the first six months and the last six months of the hospital stay 
for every individual.  Data from the in-between months were collected quarterly.  As an example, 
subject “A” was a patient at PGH from January 2002 through December 2003, therefore January 
2002 to June 2002 was recorded monthly, followed by September 2002, December 2003, March 
2003 and then monthly from July 2003 to December 2003.  Therefore a total of 15 time points 
were recorded for subject “A.”  When a patient is admitted to PGH it is because they present a 
danger to themselves or others, require continuous care, or have needs that cannot be met 
properly by a nursing facility or assisted living facility (Piedmont Geriatric Hospital, 2010).  
Hence they usually require stabilization upon admission and this is typically accomplished by 
changes in the medication regimen.  Therefore the first six months were collected in order to 
account for any changes that the alteration in medications may have on their function, behavior 
and cognition.  The last six months were collected to measure the changes in progression at the 
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end of the disease for those that had deceased at PGH and the progression to stabilization for 
those that were discharged.   
In addition to the nursing report, demographic information was collected from the physician, 
social worker and psychologist notes.  The prescription history for every month that the patient’s 
nursing report was recorded was noted.  The IRB approved collection form is included in 
Appendix 4.  This form does not include any PHI and therefore this study was approved as an 
exempt IRB protocol.   
4.1.2 Participants 
Patients were selected if they had a diagnosis of dementia and had been at PGH within the last 
six years.  Six years was chosen because the pharmacy only keeps records for six years.  These 
patients were identified by the health information management (HIM) specialist, Peggy Vaughn, 
who worked with the billing department to identify potential subjects.  There were 56 patients 
that were deceased at the time of the identification and then additional 37 patients who had to be 
contacted as they were alive and no longer at PGH.  These 37 patients had a letter sent to their 
family/representative.  There were 10 patients whose family or representative declined their 
participation or the letter did not reach them.  Therefore there were a total of 83 patients included 
in this study.   
Initially only patients with a diagnosis of AD were to be included.  After the billing records were 
checked there were only 28 patients with a primary diagnosis of dementia.  The computer billing 
program is unable to identify patients by their secondary diagnosis.  Therefore if a patient’s 
primary diagnosis is Parkinson’s disease with a secondary diagnosis of AD or dementia, then 
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they will not be added to the report.  Based on this information the diagnosis of interest was 
widened to all dementia to increase the number of potential participants in the study.   
Another method of increasing participants in the study that was attempted was to use records 
from the other state facilities that had geriatric patients with dementia.  The issue that arose was 
the measures of function, cognition and behavior varied across all of the facilities and there was 
not a clear method of standardizing the assessments between hospitals.  While PGH used the 
Functional Independence Measure Scale (FIMS), another facility, Catawba Hospital relied upon 
nursing notes rather than a specific assessment tool for the measurement of function.  Therefore 
all of the participants in this study were from PGH.   
4.1.3 Data Collection 
The student investigator (S. Dharia) went to PGH on several occasions to obtain the data. The 
sources of patient information were the medical chart and the pharmacy database, if needed, for 
prescription history.  In terms of prescription history, any prescriptions prior to 2004 had to be 
collected from the chart only. Much of the pharmacy medication record was already in the chart.  
The charts used were located in the medical records room, on microfiche, in the overflow chart 
room, or on the units.   For patients who were deceased or discharged the first two locations were 
where the majority of information was collected.  The second two locations were for patients that 
were still at PGH or that were just recently discharged.  The list of patients identified by HIM 
was used to find the charts.  As mentioned above, the majority of information was collected from 
the healthcare notes.  The nursing report was located in the middle section of the chart along with 
the daily medical notes.  The pharmacy monthly prescription information was found at the 
beginning of the chart.  The physician, social worker and psychologist notes were all found in the 
 69 
 
first chart that the patient had.  The majority of the patients had more than one chart as only six 
months was allocated to each one.  The records from 2000 to 2010 were reviewed for patient and 
disease specific information. Data prior to this date was not collected as the specific outcome 
assessments were not in use prior to 2000.   
Many of the patients had multiple admissions during the course of their disease progression, 
therefore only their first admission was included.  This was done to ensure that the rate of 
progression was captured with as few external influences and to limit variability on the patients’ 
progression through the disease.  Additionally, as indicated above when a patient is admitted to 
PGH, stabilization of the patient’s condition is required and therefore each admission would alter 
the rate of progression of the disease.   
As mentioned above in the study design section, data from the first six months and last six 
months, if available, were collected for each patient’s stay.  Additionally, for the months in 
between, data was collected quarterly.   
The specific data collected included age, sex, marital status, ethnicity, length of stay, number of 
admissions, residence prior to admission, education, smoking and alcohol use status, conditions 
at first admission, year of dementia diagnosis, and ChEIs and memantine use. The ChEIs and 
memantine use was collected from the charts, under the pharmacy prescriptions and the 
physician notes from admission that documented past medication history.   This data was 
collected as past research has shown that these factors may influence the progression or the 
improvement of dementia (Alzheimer’s Association 2010)( Birks J, 2006).  As mentioned above, 
PHI including name, date of birth, admission and discharge dates were not recorded to protect 
patient privacy.  This specific information was needed to identify the patient charts, collect the 
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data and match the pharmacy data from the chart with the pharmacy database.  The student 
investigator (S. Dharia) and on one occasion for one patient a gerontology student recorded the 
information.  These two students underwent required HIPPA training prior to collecting or 
recording any information.    
The coding scheme for the variables is located in Table 9.  All other variables remained 
continuous.   
Table 9: Variable Coding Scheme 
Variable Coding Scheme 
Sex “male” = 0; “female” = 1 
Marital Status 
“married” = 1  
“single” = 2 
“widowed” = 3  
“divorced” = 4  
“separated” = 5 
“unknown” = 9 
Ethnicity/Race 
“White” = 1  
“Black” = 2 
“Hispanic” = 3  
“Asian/Pacific Islander” = 4 
“Native American” = 5 
“unknown” = 9 
Residence Prior to Admission 
“home with no assistance” = 1  
“home with assistance” = 2  
“assisted living facility” = 3  
“skilled nursing facility” = 4 
“unknown” = 9 
Education 
“<K-5” = 1  
“K-5” = 2  
“6-8” = 3 
“9-12” = 4 
 “>12+” = 5 
“unknown” = 9 
Smoking 
“no” = 0  
“yes” = 1  
“unknown” = 9 
Alcohol “no” = 0  “yes” = 1 
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Variable Coding Scheme 
“unknown” = 9 
 
AD Medications 
“donepezil” = 1  
“rivastigmine” = 2  
“galantamine” = 3  
“memantine” = 4 
“unknown” = 9 
 
Conditions Present on Admission 
“yes” = 1  
“no” = 0 
“unknown” = 9 
Change in Cognition “change” = 1 “no change” = 2 
Change in Behavior “change” = 1 “no change” = 2  
 
As mentioned above, monthly medication lists were collected from the chart and the pharmacy 
dispensing database.  The pharmacy dispensing database was only searched when the 
information was not available in the chart.  If there was a disagreement between the two sources 
of prescription information, the physician notes and the nurses’ medication log were checked and 
verified.  Specifically, all medications and their dosages for each patient were collected.  The 
medication information was collected for every month that was recorded. As a clarification, 
drugs for the first six months, last six months and then quarterly in between were collected.  This 
information was used to determine the AC burden score using the ADS (Carnahan et al, 2006).   
The ADS, as mentioned in the introduction, is a non-invasive method of AC burden 
quantification.  This method assigns ratings of 0 to 3 for a list of medications. This list is in 
Appendix B.  The ratings are defined as follows, level 0 = no known AC properties; level 1 = 
potentially AC as evidenced by receptor binding studies; level 2 = AC adverse events sometimes 
noted, usually at excessive doses; and level 3 = markedly AC.  The ratings were then added 
together to determine the ADS total score.  If a medication was used as both a scheduled and as 
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needed medication then its rating was added twice.  For instance, if a patient was taking 
tolterodine (ADS = 3) for urinary incontinence, alprazolam (ADS = 1) for anxiety as needed and 
alendronate (ADS = 0) for osteoporosis, the total ADS score for this patient would be a 4.   This 
method was chosen for its use in a retrospective study using medical records.  The DBI would 
have been another option, but it only considers dose and not the level of AC activity as the ADS 
does. The ideal scale would have taken both into consideration.  
4.1.4 Assessments 
The clinical outcome of interest for the primary study objective was the change in function over 
time. This objective was to assess the function in dementia patients with varying AC burden.  To 
accomplish this, functional information was collected from the chart, specifically from the 
Functional Independence Measure Scale (FIMS) that is part of the monthly nursing report.  This 
scale was originally developed to assess functional gains in patients undergoing rehabilitation for 
a stroke.  Since then it has become widely used in rehabilitation facilities and for the 
measurement of activities of daily living (ADLs) in dementia patients (Cotter et al, 2002).  The 
FIMS is also used at Veterans Administration hospitals and in continuing care centers.  This 
measurement assesses how independent a person is on a scale of 1 to 7.  Where 1 = complete 
dependence and 7 = complete independence.  The original scale assesses the areas of self-care 
(grooming, dressing, eating, etc.), sphincter control, mobility, locomotion, communication and 
social cognition (Oczkowski et al, 1993; Amundson et al, 2010).  As a measure for ADLs in 
dementia patients the scale was modified to all areas but the communication and social cognition 
portions (Cotter et al, 2002).  A study by Cotter et al showed that this tool is as effective in 
measuring ADLs as caregiver reports (Cotter et al, 2002).  This tool would decrease the amount 
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of time spent writing a monthly note about the patient’s ADL status, which was method of 
assessment prior to 2000 at PGH.  In addition, this is a standardized method of assessing function 
when there are several nurses involved in the patients’ care.   As mentioned above the FIMS was 
first used in 2000 and then through the years it was further modified.  The original modified 
scale used at PGH in 2000 measured 13 areas including eating, grooming, bathing, dressing 
upper, dressing lower, toileting, bladder management, bowel management, bed to chair or 
wheelchair transfer, ability to transfer to toilet, tub/shower, walking or use of wheelchair, and the 
ability to use the stairs.  The newer modified version that PGH started using in 2007 only had 9 
items and did not include the transfer from bed to chair/wheelchair, transfer to the toilet, 
tub/shower transfer or use of stairs.  It not known why a modified version was used or why it was 
further shortened in 2007.   It may have been that communication and social cognition are 
impaired in the majority of patients who are admitted to PGH.  Additionally, patients never take 
the stairs at PGH and many of the patients are in wheelchairs or require assistance to the toilet or 
shower.   As the FIMS is part of the nursing report, the nursing staff fills it out.  The extent of the 
training given to the nurses on the FIMS is unknown. 
The secondary objectives were to assess the cognition and behavior in dementia patients with 
varying AC burdens.    Cognitive status and behavioral status were evaluated using the Monthly 
Nursing Recovery Summary attached to the FIMS score.  The notes provided nursing 
observations of behavior and cognition collected for each particular month.  The first page of the 
nursing report was dedicated for the documentation of behavior and cognition.  These notes were 
then interpreted only by the student investigator (S. Dharia) as a change or no change from the 
previous month or report. Change referred to worsening behavior or cognition.  In many reports, 
there were notes of “increased hitting” or “more confusion,” which were then both coded as a 
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change.  In other reports, the notes would say “1 instance of hitting” and then the next month 
would say the same thing.  This was translated as no change from the month before.  A positive 
change was rare, but if it did occur it was minor and categorized as no change.  If the positive 
change was significant then a notation would have been made on the collection form that 
behavior or cognition had improved from the month or quarter before.  There were no instances 
of significant positive change for any of the patients.   
4.1.5 Statistical Analysis 
Descriptive statistics were used to describe the data.  Also, regression analysis was used to 
explore the relationship between the outcomes and ADS scores.  Data from the collection forms 
was complied into an Excel spreadsheet.  Excel 2007 and SPSS 18.0 were used to calculate 
descriptive statistics including mean (median and range), percentages and total counts.   
Additionally, the FIMS scores were plotted to assess the distribution and assess for normality.  
The distribution was found to be a more s-shaped distribution.  Data transformations were 
performed to obtain a normal distribution.  The distributions were evaluated using the Shapiro-
Wilk test, the Q-Q plots, the histograms, and the box-plots.  The distribution was kept at normal 
and the link function as identity.  These are the pre-set model types for linear scale responses.  
For the cognitive and behavioral outcomes the model type was selected as binary logistic.  This 
was because the data was “yes/no” responses to change.   
A sample size calculation was performed using the following equation: 
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Where  is the z-score for the alpha level, which is 0.05 for a two-tailed test, and therefore 
0.025 for this situation.  The zβ is the z-score for the beta level or Type 2 error and 0.80 for 80% 
power.  The σ is the estimate of the standard deviation which is equivalent to the FIMS minimum 
score subtracted from the maximum score divided by six.  The ρ is the within-subject variance 
which is estimated to be zero in ideal cases.  δ2
The relationship between outcomes of interest and the other variables were modeled using a 
generalized estimating equation approach (GEE).  GEE was chosen over other statistical 
methods such as random effects as it makes fewer assumptions and therefore has a lower risk of 
bias.  It is consistent even if the correlation structure is misspecified (Twisk, 2003). Also it is an 
appropriate method to use when the data is longitudinal in nature as in this study.   
 refers to the minimum clinically important effect 
size.  The literature was searched to find this value, two articles relating to dementia with the 
recorded effect sizes were identified.  They were both for cognitive outcomes in dementia and 
not functional outcomes (Colcombe et al, 2003; Oken et al, 1998).  Both articles found effect 
sizes to be an average of 0.45. This value was used in this equation.  The m is the number of 
repeated of measures which in this case was the average of the number of observations for the 
patients.   Using this equation it was determined that to see a difference a sample size of 435.47 
or 436 patients was needed.  Typically sample size calculations are used in experimental studies 
and not retrospective, observational ones.  In this study, the sample size was much smaller than 
436 participants and as mentioned in section 4.1.2 reaching this number was not achievable.   
The data was reviewed and the participants with only one time point were removed as a change 
in function, cognition and behavior over time were the objectives of interest.   Following this, a 
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correlation structure was selected based on a within subject correlation structure table.  This table 
is based on the first six month time points and is displayed below as Table 10.   
Table 10: Within Subject Correlation Structure 
 Y1 Y2 Y3 Y4 Y5 Y6 
Y1 - 0.014 0.121 0.165 0.207 0.253 
Y2  - 0.109 0.138 0.179 0.226 
Y3   - 0.027 0.067 0.115 
Y4    - 0.042 0.091 
Y5     - 0.048 
Y6      - 
 
There are five correlation structures that could have been selected including independent, 
exchangeable, m-dependent, autoregressive and unstructured.  The independent structure was 
excluded as the correlations between measurements cannot be assumed to be zero.  Furthermore, 
unstructured, which assumes that all of the correlations are different, was excluded due to 
computational challenges associated with a small sample size resulting in the estimation 
algorithm failing to converge.  The autoregressive structure was initially eliminated as it works 
best with equally spaced time points.   For this analysis, time was collected quarterly with each 
of the first six months and last six months collected as well.  The data was then changed to 
accommodate this equally spaced requirement by using the first and the fourth month to run the 
analysis.  Exchangeable assumes that the correlations between measurements are equal (Twisk, 
2003).  For this data that is not the case, but it may be an appropriate structure to use.  M-
dependent assumes that correlations one measurement apart are equal, two measurements apart 
are equal and so forth.  This is a more appropriate structure, but it is less desirable for the data as 
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it is a relatively small set and m-dependent requires estimating additional parameters (Twisk, 
2003).   
The data was analyzed using these three specific structures, autoregressive, exchangeable, and 
m-dependent, for comparison purposes.  The dataset minus those with only one time point was 
used to compare the exchangeable and the m-dependent structures only.   
Additionally, a second modified dataset was created based on the patients who were at PGH for a 
minimum of six months.  This second dataset was used as the correlation structure was based on 
these results.  Exchangeable and m-dependent structures were used on this dataset.   
A third dataset was created to run an autoregressive correlation structure.  The months in this 
dataset were quarterly.  Therefore for the first six months, months 2, 3, 5, and 6 were removed 
and then the same was done for the last six months.    
Another analysis was run using the significant variables from the first analysis for all of the 
correlation structures and their corresponding data sets.  Additionally, the insignificant variables 
that may have influenced them were included.  The insignificant variables that may have caused 
a change of 20% or more in the coefficients of the significant variables were the ones that were 
included in this second analysis.  This assesses for potential confounding in the variables.  If 
insignificant variables cause a 20% or greater change in the estimates then it is said to be a 
potential confounder.   
There were a total of 10 outputs for the different models listed above.  The use of three 
correlation structures was only used for the assessment of the functional outcome.  The cognitive 
and behavioral outcomes were evaluated using GEE regression for categorical data and used the 
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exchangeable structure as they are coded yes/no responses. There are a total of four outputs for 
both of these outcomes.    
A goodness of fit test (QIC) was performed using SPSS and was used to evaluate how well the 
model fits the observations.  This was then useful in determining which of the correlation 
structures was more appropriate.  A Huber-White sandwich estimator was used as a way to 
ensure that the variances were robust.  Specifically, robust variances are important as they 
provide accurate assessments of the sample-to-sample variability of the parameter estimates even 
if the model is misspecified (Norusis, 2008).    
For the test of model effects, Type III, was selected for all analysis as it does not depend on the 
entry order of the variables like Type I does.  Test Type III is typically preferred unless order of 
the variables is important, which in this case it is not.     
There were several independent variables evaluated for the three outcomes including age, sex, 
marital status, ethnicity, length of stay, number of admissions, residence prior to admission, 
education, smoking and alcohol use status, year of dementia diagnosis, functional comorbidity 
index, constipation, and ChEI and memantine use.   
The functional comorbidity index (FCI) is a tool that predicts function for patients who have 
comorbid diseases such as diabetes or COPD.  The FCI was more effective in evaluating an 
association to physical function compared with the Charlson Comorbidity and the Kaplan-
Ferinstein indices (Groll et al, 2005).  It includes most common diagnosis, but as it is based on 
secondary data, there may be others that should have been included.  Overall the FCI is a useful 
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tool and the only general population-based functional index.  This tool assigns “1” if a person 
has one of the 18 diseases and “0” if they do not (Groll et al, 2005).     
There was one select condition that may be considered a side effect of the use of AC medications 
that was included in this analysis, constipation. The other disease states recorded were not 
included in the analysis as only those in the FCI have been shown to have an association with 
functional outcomes.  These conditions were still included in the descriptive statistics.   
The α-level was set at 0.05.  Statistical analyses were performed using SPSS Version 18.0 for 
Windows. 
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Chapter 5 
Results 
5.1 Results 
5.1.1 Descriptive Results 
There were a total of 83 subjects included in this study with a median age of 77 years and a range 
of 65 to 94 years at admission.  Table 11 displays the demographics of the patients. The majority 
of the subjects were either married or widowed white males that were living in a nursing home or 
hospital prior to being admitted to PGH.  Furthermore, the majority graduated high school or had 
some college.  The participants were at PGH for a median of 536 days, with a range of 13 to 
2973 days.  
While all of the patients had a diagnosis of dementia, only 33.7% were taking a cognitive-
enhancing medication.  Of those 36 patients taking (or did so previously) a ChEI or memantine, 
the majority were taking donepezil as their first or second cognitive-enhancing medication.  
There were eight participants taking two cognitive-enhancing treatments during their stay a 
PGH.  None of the patients took galantamine as their second medication.  The median ADS score 
was 3.0 with the majority of patients having ADS scores ranging from 1 to 3.  There were several 
AC medications that this sample received, divalproex, olanzapine, lorazepam, sertraline, and 
furosemide were the most commonly used.   
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Table 11: Demographics 
Age (Years) at Admission Mean ± SD 
Average 78 ± 6 
Sex  % (N) 
Female 32.5%  (27) 
Male 67.5%  (56) 
Race/ Ethnicity % (N) 
White 63.9%  (53) 
Black 32.5%  (27) 
Hispanic 1.2%  (1) 
Asian/Pacific Islander 1.2%  (1) 
American Indian 1.2%  (1) 
Marital Status % (N) 
Married 34.9%  (29) 
Single 8.4%  (7) 
Widowed 31.3%  (26) 
Divorced 20.5%  (17) 
Separated  1.2%  (1) 
Unknown 3.6%  (3) 
Highest Education Achieved (Years) % (N) 
<K-5 10.8%  (9) 
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K-5 2.4%  (2) 
6-8 21.7%  (18) 
9-12 36.1%  (30) 
>12+ 24.1%   (20) 
Unknown 4.8%  (4) 
Residence Prior to Admission % (N) 
Home w/ no Assistance 15.7%  (13) 
Home w/ Assistance 19.3%  (16) 
ALF 8.4%  (7) 
SNF 55.4%  (46) 
Unknown 1.2%  (1) 
LOS   
Range (days)* 13-2973 
Mean (days)* 769 ± 756 
Median (days)* 536 
Mean (months)^ 19.6 ± 20.1  
* number of days patient was in hospital during 1st admission 
^ number of months from first FIMS (no earlier than 2000) to last FIMS score 
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As shown in Table 12, the FIMS score had a wide range with a median of 14.  None of the 
patients had a maximal FIMS score of 81, the highest was 65.  Due to this wide range of FIMS 
score, a test of normality was performed.  The Q-Q plot for the non-transformed data is located 
in Figure 1.   The Shapiro-Wilks test was used to assess for normality and it was significant with 
a p-value <0.01 indicating that the data were not normally distributed.  Several methods were 
used to transform the data to obtain normality.  None of the methods produced a non-significant 
Shapiro-Wilk’s test.  The Q-Q plots were assessed and the natural logarithmic transformation of 
the data produced a normal distribution visually compared to the other transformations (Figure 
2).  Additionally, the histogram and box-plots were assessed to determine the most appropriate 
data transformation.    The plots and the histogram using the logarithmic transformation were 
much more normal visually than the other transformations and the original scores.  Normality is 
not an assumption of GEE and research using GEE has shown to produce robust results with 
skewed data (Lee et al, 2007).  Therefore the logarithmic distribution was used in the analysis.    
Table 12: AD Treatment and Outcomes 
AD Treatment % (N) 
Yes 33.7%  (28) 
Previous 9.6%  (8) 
First AD Medication* % (N) 
donepezil 50.0%  (18) 
rivastigmine 13.9%  (5) 
galantamine 11.1%  (4) 
memantine 25%  (9) 
Second AD Medication** % (N) 
donepezil 62.5%  (5) 
rivastigmine 25.0%  (2) 
memantine 12.5% (1) 
ADS   
Range 0.0-11 
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Mean ± Std Dev  3.0 ± 2.1 
FIMS Score   
Range 8.0 - 65.0 
Mean ± Std Dev  19.1 ± 13.0 
Change in Cognition^ % (N) 
Yes 40.9% (464) 
Change in Behavior^ % (N) 
Yes 69.3% (786) 
* Total n = 36 
** Total n = 8 
^ Total n = 1135, the number of total observations 
 
Figure 1: Distribution of FIMS Scores 
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Figure 2: Distribution of the Natural Log of the FIMS Scores 
 
Table 13 displays the health related demographics.  The majority of patients were non-smokers 
and about half either drank or were previous drinkers.  There were some patients that had 
developed dementia due to heavy alcohol use.  The most common disease conditions at 
admission were hypertension and other cardiovascular disorders, such as myocardial infarction 
(MI), stroke, congestive heart failure (CHF), coronary artery disease (CAD), and peripheral 
vascular disease (PVD).   There were some conditions listed on the collection form that were not 
present in this patient population including certain gastrointestinal (GI) conditions such as 
diarrhea and nausea/vomiting.  The average FCI was 2.2 with a range of 0 to 22.  The FCI 
accounted for several disease states including, arthritis, osteoporosis, asthma, chronic obstructive 
pulmonary disease (COPD), angina, CHF, MI, Parkinson’s disease (PD), stroke, PVD, diabetes, 
upper gastrointestinal diseases, depression, anxiety, visual impairment, hearing impairment, 
degenerative disc disease including osteoporosis, and obesity.     
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Table 13: Health Related Demographics 
Smoking % (N) 
No 61.4% (51) 
Previous 27.7% (23) 
Unknown 4.8%  (4) 
Alcohol % (N) 
No 47% (39) 
Previous 42.2% (35) 
Unknown 3.6%  (3) 
Disease States on Admission % (N) 
HTN 63.9%  (53) 
Other CV 53.0%  (44) 
Constipation 44.6%  (37) 
High Cholesterol 27.7%  (23) 
Diabetes 26.5%  (22) 
Thyroid Conditions 22.9%  (19) 
COPD 22.9%  (19) 
Seizures 19.3%  (16) 
TBI 13.3%  (11) 
Urinary Incontinence 10.8%  (9) 
Arrhythmias 8.4%  (7) 
Depression 7.2%  (6) 
Delirium/Confusion 7.2%  (6) 
Cancer 6.0%  (5) 
Loss of Coordination 6.0%  (5) 
PD 6.0%  (5) 
Agitation 6.0%  (5) 
Asthma 3.6%  (3) 
Loss of Appetite 2.4% (2) 
Bradycardia 2.4% (2) 
Eyeglasses 2.4% (2) 
Hearing Aids 1.2% (1) 
Abdominal Cramps 1.2% (1) 
Tachycardia 1.2% (1) 
Pneumonia 0% (0) 
Vomiting 0% (0) 
Nausea 0% (0) 
Diarrhea 0% (0) 
Dry Mouth 0% (0) 
Clots 0% (0) 
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5.1.2 Functional Outcomes 
The use of the FCI enabled important variables to remain in the dataset, including the use of 
visual or hearing aids.  Otherwise these would have been removed due to less than five values 
per disease state.  Additionally, the patients who were only at PGH for a month or less were 
excluded. Therefore a total of 79 patients were included in the final analyses.  There were a total 
of 1131 time points included for all 79 patients and none of the patients or time points were 
excluded.  The minimum number of months was 2 and the maximum number of months for an 
individual was 40.  Table 14 provides a description of the patients that were removed and why.  
Table 14: Patients Excluded from the Analysis 
 
Patient 
Number 
Dataset Removed From Reason for Removal (1 Time Point = 1 
Month) 
5 79 Patients / AR < 2 time points  
6 66 Patients / AR  < 6 time points 
15 66 Patients / AR < 6 time points 
16 79 Patients / AR < 2 time points  
17 66 Patients / AR < 6 time points 
31 66 Patients / AR < 6 time points 
36 66 Patients  < 6 time points 
37 79 Patients / AR < 2 time points  
38 66 Patients / AR < 6 time points 
39 79 Patients / AR < 2 time points  
40 66 Patients / AR < 6 time points 
41 66 Patients  < 6 time points 
56 N/A Patient record not found at PGH 
63 66 Patients / AR < 6 time points 
64 66 Patients  < 6 time points 
65 66 Patients / AR < 6 time points 
70 66 Patients / AR < 6 time points 
71 66 Patients / AR < 6 time points 
 88 
 
5.1.2.1 Autoregressive (AR1) Structure 
There were 69 subjects and total of 618 time points for the dataset that was used for a GEE with 
an AR1 correlation structure.  The relationship between logarithmic FIMS scores and ADS 
scores were assessed univariately.  As shown below (Table 15), there is not an association 
between ADS and FIMS scores.   
Table 15: Relationship between FIMS and ADS Scores 
Parameter B 
Std. 
Error 
95% Wald 
Confidence Interval 
Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) 2.859 .0585 2.744 2.974 2384.738 1 .000 
ADS -.019 .0111 -.041 .002 3.026 1 .082 
 
To assess which of the other variables are important predictors the rest of the variables were run 
univariately.  The following variables were significant, FIMSMonth (time), race, current use of 
ChEIs or memantine, residence, history of alcohol use, and FCI score.  The parameter estimates 
for these variables and ADS score are included in Table 16.   
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Table 16: Autoregressive Parameter Estimates 
 
Parameter 
B 
Std. 
Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) 3.559 .3781 2.818 4.300 88.598 1 .000 
FIMSMonth -.015 .0023 -.019 -.010 39.356 1 .000 
[ChEIMemantine=0] .252 .1056 .045 .459 5.686 1 .017 
[ChEIMemantine=1] .205 .1178 -.026 .436 3.016 1 .082 
[ChEIMemantine=2] 0a . . . . . . 
[Race=1] -.574 .0825 -.735 -.412 48.423 1 .000 
[Race=2] -.460 .1377 -.730 -.190 11.143 1 .001 
[Race=3] -.220 .1457 -.506 .065 2.290 1 .130 
[Race=5] 0a . . . . . . 
[Alcohol=0] -.545 .3606 -1.252 .161 2.287 1 .130 
[Alcohol=1] -.500 .3425 -1.171 .171 2.131 1 .144 
[Alcohol=2] -.450 .3541 -1.144 .244 1.616 1 .204 
[Alcohol=9] 0a . . . . . . 
[Residence=1] .415 .1667 .089 .742 6.211 1 .013 
[Residence=2] .556 .1602 .242 .870 12.066 1 .001 
[Residence=3] .048 .1676 -.281 .376 .082 1 .775 
[Residence=4] .229 .0996 .034 .424 5.282 1 .022 
[Residence=9] 0 . a . . . . . 
ADS -.009 .0102 -.029 .011 .773 1 .379 
FCI .018 .0098 -.001 .037 3.264 1 .071 
(Scale) .215       
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Model fit is assessed by the quasi log likelihood under the independence criterion (QIC). The 
QIC is similar to the maximum likelihood function used in GEE.   The QIC offers a rough guide 
of goodness of fit and can be used to compare nested models when choosing the best subset of 
predictors (Norusis, 2008).  A model with a QIC that is smaller reflects that it is more effective at 
predicting than a model with a larger QIC (Norusis, 2008).  Models with different predictor 
variables cannot be compared to each other using the QIC, only the models with different 
correlation structures and the same predictors.  In the model displayed in Table 16, the QIC was 
250.65. The QICs for the five models is located in Table 25.  
5.1.2.2 Exchangeable Structure – 79 Patient Dataset  
The second correlation structure evaluated was exchangeable with 79 patients, followed by the 5-
dependent correlation structure. This 79 patient dataset includes all patients with at least two 
time points.  Then both structures were run using the dataset with only 66 patients.  This dataset 
includes only those with at least six time points.  The description of the patients who were 
excluded and why are located in Table 14.   
When the exchangeable results are reviewed, there are 1131 observations included without any 
missing data.  The relationship between logarithmic FIMS scores and ADS scores were assessed 
univariately.  As shown below (Table 17), there is not an association between ADS and FIMS 
scores.   
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Table 17: Exchangeable Structure – Relationship between FIMS and ADS Scores for 79 
Patients 
Parameter B 
Std. 
Error 
95% Wald Confidence 
Interval 
Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) 2.929 .0882 2.756 3.101 1102.166 1 .000 
ADS -.030 .0234 -.076 .016 1.676 1 .195 
 
To assess which of the other variables are important predictors the rest of the variables were run 
univariately.  The following variables were significant, FIMSMonth (time), race, marital status, 
length of stay (LOS), and residence.  The parameter estimates for these variables and ADS score 
are included in Table 18.   Marital status and LOS are no longer significant in this total model, 
but remain as they were univariately significant with the logarithmic transformation of FIMS 
score.  Additionally, increased LOS is known to be associated with poorer outcomes.  
Table 18: Exchangeable Structure Model for 79 Patients 
 
Parameter 
B Std. Error 
95% Wald 
Confidence Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) 3.299 .2895 2.732 3.867 129.852 1 .000 
[Race=1] -.411 .2026 -.808 -.014 4.119 1 .042 
[Race=2] -.245 .2083 -.653 .164 1.380 1 .240 
[Race=3] .200 .2159 -.224 .623 .854 1 .355 
[Race=4] .352 .2632 -.163 .868 1.793 1 .181 
[Race=5] 0a . . . . . . 
[MaritalStatus=1] -.232 .2002 -.624 .160 1.343 1 .247 
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Parameter 
B Std. Error 
95% Wald 
Confidence Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
[MaritalStatus=2] -.076 .2688 -.603 .451 .079 1 .778 
[MaritalStatus=3] -.311 .2066 -.716 .094 2.272 1 .132 
[MaritalStatus=4] -.220 .2247 -.660 .221 .958 1 .328 
[MaritalStatus=5] -.457 .2679 -.982 .069 2.903 1 .088 
[MaritalStatus=9] 0a . . . . . . 
[Residence=1] .527 .1725 .189 .865 9.325 1 .002 
[Residence=2] .699 .1488 .407 .991 22.048 1 .000 
[Residence=3] .044 .1664 -.282 .370 .070 1 .791 
[Residence=4] .208 .0911 .030 .387 5.224 1 .022 
[Residence=9] 0a . . . . . . 
FIMSMonth -.014 .0024 -.019 -.010 34.970 1 .000 
ADS -.023 .0178 -.058 .012 1.723 1 .189 
LOS 5.871E-5 6.5490E-5 -6.965E-5 .000 .804 1 .370 
(Scale) .224       
 
5.1.2.3 5-Dependent Structure – 79 Patient Dataset 
When the 5-dependent results are reviewed, there are 1131 observations included without any 
missing data. The relationship between logarithmic FIMS scores and ADS scores were assessed 
univariately.  As shown below (Table 19), there is not an association between ADS and FIMS 
scores.   
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Table 19: 5-Dependent Structure – Relationship between FIMS and ADS Scores for 79 
Patients 
Parameter B 
Std. 
Error 
95% Wald Confidence 
Interval 
Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) 2.790 .0628 2.667 2.913 1973.088 1 .000 
ADS .005 .0130 -.021 .030 .122 1 .727 
 
To assess which of the other variables are important predictors the rest of the variables were run 
univariately.  The following variables were significant, FIMSMonth (time), residence, history of 
smoking and alcohol use, race, and length of stay (LOS).  The parameter estimates for these 
variables and ADS score are included in Table 20.  History of smoking and alcohol use, and LOS 
are no longer significant in this total model, but remain as they were univariately significant with 
the logarithmic transformation of FIMS score.  Additionally, history of smoking, and alcohol, 
and increased LOS are known to be associated with poorer outcomes.   
When the exchangeable and the 5-dependent reduced 2 models are compared the QICs are 
489.38 and 451.31, respectively.  Based on the goodness of fit, the 5-dependent is a better model 
when the 79 patient dataset is used.    
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Table 20: 5-Dependent Structure Model for 79 Patients 
 
Parameter 
B Std. Error 
95% Wald 
Confidence Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) 3.517 .2765 2.975 4.059 161.814 1 .000 
[Race=1] -.690 .0647 -.817 -.563 113.879 1 .000 
[Race=2] -.524 .0989 -.718 -.331 28.141 1 .000 
[Race=3] .029 .1624 -.290 .347 .031 1 .861 
[Race=4] .211 .1423 -.068 .490 2.200 1 .138 
[Race=5] 0a . . . . . . 
[Residence=1] .515 .1703 .181 .848 9.131 1 .003 
[Residence=2] .559 .1384 .288 .831 16.336 1 .000 
[Residence=3] .086 .1616 -.231 .402 .281 1 .596 
[Residence=4] .224 .0993 .030 .419 5.104 1 .024 
[Residence=9] 0a . . . . . . 
[Smoking=0] -.036 .2855 -.596 .523 .016 1 .899 
[Smoking=1] .230 .3112 -.380 .840 .545 1 .461 
[Smoking=2] .014 .2869 -.548 .576 .002 1 .961 
[Smoking=9] 0a . . . . . . 
[Alcohol=0] -.332 .3486 -1.015 .351 .907 1 .341 
[Alcohol=1] -.385 .3334 -1.038 .269 1.331 1 .249 
[Alcohol=2] -.249 .3343 -.904 .406 .555 1 .456 
[Alcohol=9] 0a . . . . . . 
FIMSMonth -.014 .0028 -.020 -.009 25.362 1 .000 
ADS .016 .0128 -.009 .042 1.635 1 .201 
LOS 8.434E-5 5.9287E-5 -3.186E-5 .000 2.024 1 .155 
(Scale) .208       
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5.1.2.4 Exchangeable Structure – 66 Patient Dataset 
When the exchangeable results for the smaller dataset are reviewed, there are 1087 observations 
included without any missing data.  The relationship between logarithmic FIMS scores and ADS 
scores were assessed univariately.  As shown below (Table 21), there is not an association 
between ADS and FIMS scores.   
Table 21: Exchangeable Structure – Relationship between FIMS and ADS Scores for 66 
Patients 
Parameter B 
Std. 
Error 
95% Wald Confidence 
Interval 
Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) 2.866 .0894 2.691 3.041 1027.506 1 .000 
ADS -.031 .0235 -.077 .016 1.691 1 .193 
 
To assess which of the other variables are important predictors the rest of the variables were run 
univariately.  The following variables were significant, FIMSMonth (time), FCI score, history of 
smoking and alcohol use, race, residence, and current use of ChEIs or memantine.  The 
parameter estimates for these variables and ADS score are included in Table 22.  History of 
smoking and use of ChEIs and memantine are no longer significant in this total model, but 
remain as they were univariately significant with the logarithmic transformation of FIMS score.  
Additionally, history of smoking is known to be associated with poorer outcomes.   
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Table 22: Exchangeable Structure Model for 66 Patients 
Parameter 
B Std. Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square df Sig. 
(Intercept) 3.387 .3172 2.765 4.009 114.01
8 
1 .000 
FCI .036 .0096 .017 .055 14.096 1 .000 
[Race=1] -.433 .0982 -.626 -.241 19.474 1 .000 
[Race=2] -.335 .1547 -.638 -.031 4.681 1 .030 
[Race=3] .243 .1898 -.129 .615 1.640 1 .200 
[Race=5] 0 . a . . . . . 
[ChEIMemantine=0] .014 .1439 -.268 .296 .009 1 .924 
[ChEIMemantine=1] -.055 .1533 -.356 .245 .130 1 .719 
[ChEIMemantine=2] 0a . . . . . . 
[Smoking=0] .227 .2425 -.248 .703 .878 1 .349 
[Smoking=1] .541 .2657 .021 1.062 4.152 1 .042 
[Smoking=2] .258 .2539 -.239 .756 1.035 1 .309 
[Smoking=9] 0a . . . . . . 
[Residence=1] .490 .2540 -.008 .988 3.723 1 .054 
[Residence=2] .600 .1894 .229 .972 10.038 1 .002 
[Residence=3] .027 .2507 -.464 .519 .012 1 .913 
[Residence=4] .219 .1577 -.090 .528 1.931 1 .165 
[Residence=9] 0a . . . . . . 
[Alcohol=0] -.574 .2742 -1.111 -.036 4.380 1 .036 
[Alcohol=1] -.684 .2261 -1.128 -.241 9.163 1 .002 
[Alcohol=2] -.527 .2599 -1.037 -.018 4.114 1 .043 
[Alcohol=9] 0a . . . . . . 
ADS -.026 .0183 -.062 .010 2.070 1 .150 
FIMSMonth -.014 .0024 -.019 -.009 35.340 1 .000 
(Scale) .221       
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5.1.2.5 5-Dependent Structure – 66 Patient Dataset 
When the 5-dependent results for the smaller dataset are reviewed, there are 1087 observations 
included without any missing data.  The relationship between logarithmic FIMS scores and ADS 
scores were assessed univariately.  As shown below (Table 23), there is not an association 
between ADS and FIMS scores.   
Table 23: 5-Dependent Structure – Relationship between FIMS and ADS Scores for 66 
Patients 
Parameter B 
Std. 
Error 
95% Wald Confidence 
Interval 
Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) 2.753 .0641 2.628 2.879 1845.427 1 .000 
ADS .005 .0132 -.021 .031 .136 1 .712 
 
To assess which of the other variables are important predictors the rest of the variables were run 
univariately.  The following variables were significant, FIMSMonth (time), FCI score, history of 
smoking and alcohol use, race, residence, and current use of ChEIs or memantine. The parameter 
estimates for these variables and ADS score are included in Table 24. All of the predictors 
except for time and race were no longer significant in the combined model.  They were left in as 
they had a significant relationship with FIMS score and many are known to be associated with 
worsening outcomes in dementia.  
When the exchangeable and the 5-dependent reduced 2 models are compared the QIC is 500.14 
and 420.58, respectively.  Based on the goodness of fit, the 5-dependent is a better model.   
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When all five models are compared and their QIC’s are reviewed, Table 25, the autoregressive 
correlation structure is the best, with the lowest QIC that is at least half the other models.   
Table 24: 5-Dependent Structure Model for 66 Patients 
Parameter 
B 
Std. 
Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) 3.421 .2984 2.837 4.006 131.505 1 .000 
FCI .010 .0117 -.013 .033 .769 1 .380 
[ChEIMemantine=0] .213 .1044 .008 .418 4.154 1 .042 
[ChEIMemantine=1] .189 .1124 -.031 .410 2.838 1 .092 
[ChEIMemantine=2] 0a . . . . . . 
[Race=1] -.634 .0825 -.795 -.472 58.975 1 .000 
[Race=2] -.464 .1292 -.717 -.211 12.911 1 .000 
[Race=3] -.048 .1766 -.394 .298 .074 1 .786 
[Race=5] 0a . . . . . . 
[Residence=1] .324 .1967 -.062 .709 2.709 1 .100 
[Residence=2] .325 .1667 -.002 .652 3.802 1 .051 
[Residence=3] -.106 .1937 -.486 .273 .301 1 .583 
[Residence=4] .090 .1147 -.135 .315 .617 1 .432 
[Residence=9] 0 . a . . . . . 
[Smoking=0] .270 .2666 -.253 .792 1.024 1 .312 
[Smoking=1] .399 .2782 -.146 .944 2.060 1 .151 
[Smoking=2] .317 .2751 -.222 .856 1.328 1 .249 
[Smoking=9] 0 . a . . . . . 
[Alcohol=0] -.611 .2864 -1.173 -.050 4.552 1 .033 
[Alcohol=1] -.587 .2469 -1.071 -.103 5.641 1 .018 
[Alcohol=2] -.505 .2727 -1.040 .029 3.436 1 .064 
[Alcohol=9] 0a . . . . . . 
ADS .020 .0136 -.007 .046 2.079 1 .149 
FIMSMonth -.012 .0023 -.017 -.008 29.370 1 .000 
        
 
 99 
 
 
Table 25: Goodness of Fit for Five Models 
Model Goodness of Fit (QIC) 
Autoregressive 250.65 
Exchangeable (79 patients) 489.38 
5-Dependent (79 patients) 451.31 
Exchangeable (66 patients) 500.14 
5-Dependent (66 patients) 420.58 
 
5.1.3 Cognitive Outcomes 
For the secondary outcome of cognition, the exchangeable and autoregressive structures were 
used.  Exchangeable structure was run using the dataset with 66 patients as this produced a better 
model compared to the one that used all 79 patients.  The autoregressive structure was run using 
the dataset with 69 patients with time measured quarterly.  This was based on the fact that these 
are the two most common structures used for binary data (Lee et al, 2007). 
When the model was run using the datasets, there was an error obtained relating to convergence.  
Therefore, a correlation table for all of the variables and the outcome of cognition was run.  This 
table displayed a significant correlation of greater than 0.5 for LOS and FIMS Month.  As a 
result LOS was removed and the analysis was re-run.  The same error message relating to the 
inability of the model to reach convergence appeared.  It was then hypothesized that the model 
was over parameterized; therefore each variable was individually run against the outcome of 
cognition.   
The relationship between cognitive outcomes and ADS scores using the exchangeable and 
autoregressive structures are located in Tables 26. 
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Table 26: Relationship between Cognition and ADS Scores  
Exchangeable Structure 
Parameter B 
Std. 
Error 
95% Wald 
Confidence Interval 
Hypothesis Test 
   Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) -.172 .2196 -.602 .259 .611 1 .435 
ADS -.033 .0554 -.142 .076 .351 1 .553 
 
AR1 Structure 
Parameter B 
Std. 
Error 
95% Wald 
Confidence Interval 
Hypothesis Test 
   Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) -.400 .1893 -.771 -.029 4.469 1 .035 
ADS .011 .0428 -.073 .095 .070 1 .792 
 
The relationship is shown above and there is not an association between ADS scores and 
cognition using either of the two structures.  There were other variables that were significant 
predictors of change in cognition for the exchangeable structure.  These included race, residence, 
presence of constipation, and time (FIMS Month).   The same procedure was done for the AR1 
structure and the significant variables were presence of constipation and time.  The parameter 
estimates for both structures with only the significant variables are located in Table 27.  The 
goodness-of-fit tests were evaluated between the two structures.  Again, the autoregressive 
structure had a smaller QIC of 1187.83 compared to 1973.33 for the exchangeable structure.  
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The model that predicts the outcome variable of change in cognition is the autoregressive 
correlation structure.  The effects that were significant and therefore predictive of the outcome 
include time and presence of constipation on admission.    
Table 27: Cognitive Outcome – AR1 and Exchangeable Structure  
Parameter Estimates for Significant Variables for the AR1 Structure 
Parameter 
B 
Std. 
Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) -.132 .1966 -.517 .253 .450 1 .502 
[Constipation=1] .927 .2719 .394 1.460 11.630 1 .001 
[Constipation=0] 0 . a . . . . . 
FIMSMonth -.031 .0072 -.045 -.017 18.905 1 .000 
 
Parameter Estimates for Significant Variables for Exchangeable Structure 
Parameter 
B 
Std. 
Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) -1.172 .2693 -1.700 -.644 18.929 1 .000 
[Race=3] -2.140 .2131 -2.558 -1.723 100.875 1 .000 
[Race=2] -.296 .2631 -.812 .219 1.269 1 .260 
[Race=1] -.366 .2583 -.872 .141 2.003 1 .157 
[Race=0] 0 . a . . . . . 
[Residence=4] 1.371 .2543 .872 1.869 29.055 1 .000 
[Residence=3] .991 .2887 .425 1.557 11.779 1 .001 
[Residence=2] 1.366 .3983 .585 2.146 11.757 1 .001 
[Residence=1] 1.361 .3721 .632 2.090 13.378 1 .000 
[Residence=0] 0 . a . . . . . 
[Constipation=1] .962 .2865 .400 1.524 11.274 1 .001 
[Constipation=0] 0 . a . . . . . 
LOS -.001 .0002 -.001 .000 10.693 1 .001 
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5.1.4 Behavioral Outcomes 
The other secondary outcome of behavior was also evaluated using the exchangeable structure 
and autoregressive structures.  The same warnings associated with cognition emerged when the 
model was run with all of the variables.  Therefore each variable was run univariately with 
behavior and then the significant variables were run together.    
The relationship between cognitive outcomes and ADS scores using the exchangeable and 
autoregressive structures are located in Tables 28. 
Table 28: Relationship between Behavior and ADS Scores 
Exchangeable Structure 
Parameter B 
Std. 
Error 
95% Wald 
Confidence Interval 
Hypothesis Test 
   Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) .853 .1971 .467 1.239 18.733 1 .000 
ADS -.001 .0497 -.098 .096 .000 1 .983 
 
AR1 Structure 
Parameter B 
Std. 
Error 
95% Wald 
Confidence Interval 
Hypothesis Test 
   Lower Upper 
Wald 
Chi-
Square 
df Sig. 
(Intercept) .875 .2133 .457 1.293 16.820 1 .000 
ADS .005 .0538 -.100 .111 .010 1 .921 
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The relationship is shown above and there is not an association between ADS scores and 
behavior using either of the two structures.  There were other variables that were significant 
predictors of change in behavior.  The parameter estimates for the autoregressive and 
exchangeable structures are located in Table 29.  For the AR structure the following were the 
significant variables, time, race, age, presence of constipation, and residence.   For the 
exchangeable structure the significant variables were time, race, marital status, smoking and 
presence of constipation.   
The goodness-of-fit tests were evaluated between the two structures.  Again, the autoregressive 
structure had a smaller QIC of 1465.44 compared to 2489.34 for the exchangeable structure.  
Table 29: Behavioral Outcomes using AR1 and Exchangeable Structure 
Parameter Estimates for Significant Variables for AR1 Structures 
Parameter 
B 
Std. 
Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) 3.914 1.6627 .655 7.173 5.541 1 .019 
[Constipation=1] .683 .3544 -.012 1.377 3.713 1 .054 
[Constipation=0] 0 . a . . . . . 
[Residence=4] 1.678 .2774 1.135 2.222 36.611 1 .000 
[Residence=3] 1.028 .3365 .368 1.687 9.331 1 .002 
[Residence=2] 1.560 .5475 .487 2.633 8.122 1 .004 
[Residence=1] .987 .3773 .247 1.726 6.840 1 .009 
[Residence=0] 0 . a . . . . . 
[Race=3] -2.287 .2624 -2.801 -1.772 75.932 1 .000 
[Race=2] .252 .3312 -.398 .901 .577 1 .447 
[Race=1] .817 .2470 .333 1.301 10.942 1 .001 
[Race=0] 0 . a . . . . . 
Age -.055 .0237 -.102 -.009 5.396 1 .020 
FIMSMonth -.024 .0056 -.035 -.013 18.331 1 .000 
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Parameter Estimates for Significant Variables for Exchangeable Structure 
Parameter 
B Std. Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
(Intercept) -3.289 .7094 -4.679 -1.899 21.495 1 .000 
[Race=0] 5.212 .4731 4.285 6.139 121.382 1 .000 
[Race=1] 2.652 .2170 2.227 3.078 149.384 1 .000 
[Race=2] 3.141 .3459 2.463 3.819 82.465 1 .000 
[Race=3] 0 . a . . . . . 
[MaritalStatus=0] 1.134 .9743 -.776 3.043 1.354 1 .245 
[MaritalStatus=1] 1.397 .4206 .573 2.222 11.031 1 .001 
[MaritalStatus=2] .547 .3471 -.133 1.227 2.482 1 .115 
[MaritalStatus=3] .905 .4802 -.036 1.846 3.549 1 .060 
[MaritalStatus=4] 1.175 .5513 .094 2.255 4.540 1 .033 
[MaritalStatus=5] 0 . a . . . . . 
[Smoking=0] 1.006 .3447 .331 1.682 8.526 1 .004 
[Smoking=1] .611 .5177 -.404 1.625 1.392 1 .238 
[Smoking=2] 1.489 .4168 .672 2.306 12.761 1 .000 
[Smoking=3] 0 . a . . . . . 
[Constipation=0] -.567 .2393 -1.036 -.098 5.615 1 .018 
[Constipation=1] 0 . a . . . . . 
FIMSMonth -.024 .0064 -.037 -.012 14.697 1 .000 
 
5.1.5 Summary of Results 
In this study there are three outcomes of interest with the use of AC medications.  Function, was 
the primary outcome of interest and several models using different sized datasets were compared.  
By altering the recorded arrangement of time from the first and last consecutive six months with 
time measured quarterly between these time periods, to a more uniform time structure made a 
difference in determining the model with the best predictive ability. This structure with the best 
predictive ability was the AR1 one, based on its QIC value.   
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An association between anticholinergic burden, using ADS scores, and function was not found.  
The p-values shown in Tables 15-23, demonstrate the burden was not statistically associated with 
function.  The p-value in Table 15, using the AR1 structure, suggested that burden might have an 
effect on function, but when the other significant variables were included in an analysis, the 
variable became not significant.   
There were other variables that were associated with function using the AR1 structure.  These 
include, time (FIMSMonth), race, current use of ChEIs or memantine, residence, history of 
alcohol use, and FCI score.  Higher FIMS scores or improved function was negatively associated 
with time (-.02) and White (-.57) or Black (-.46) race.  The higher functional scores were 
positively associated with the use of memantine or a ChEIs (.21) and living at home (with or 
without assistance) prior to admission to PGH (.556 and .415).  The other variables were no 
longer significant in the combined model.  Individually, prior use of alcohol (-.67) had a negative 
relationship with higher function.  Additionally, FCI (.03) had a positive association with 
increased FIMS scores. The individual associations between these six variables and function 
were all highly significant.   
The second outcome of interest was cognition, which was a binomial variable.  There were two 
correlation structures that were used to identify the best model for this outcome.  Exchangeable 
and autoregressive were the two structures compared.  The results identified that the 
autoregressive was the better model  
Burden was not associated with cognitive outcomes.  The variable was highly insignificant as a 
predictor of change in cognition.  The variables that were statistically significant as predictors of 
change in cognition include the presence of constipation on admission and time.  Time (-.03) was 
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negatively associated and the presence of constipation (.93) was positively associated with 
change in cognition.  This is shown in Table 27.   
The third outcome of interest was behavior, also a binomial variable.  Two structures, 
exchangeable and autoregressive were compared.  The autoregressive structure was again the 
more robust of the two and produced a better model.  In this model, burden was not associated 
with change in behavior.  There were other variables that were statistically significant with 
change in behavior and these include time, race, age, presence of constipation, and residence.  
Time was negatively (-.02) associated with change in behavior as was age (-.06) and White race 
(-.79).  Presence of constipation on admission (.68) and any residence prior to admission was 
positively associated with a change in behavior as shown in Table 29.   
When all of the variables are considered, time is a predictor of all three outcomes.  Additionally, 
there other variables predictive of two of the outcomes including race, residence, and presence of 
constipation on admission.   
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Chapter 6 
Discussion and Conclusions 
 
6.1 Discussion 
Older adults are at increased risk of developing negative side effects and adverse events from 
medications, especially those with AC activity.   This is suggested to be true for older adults 
with dementia as well.  There is an increasing amount of evidence that consequences including 
increased cognitive impairment, physical impairment and rapid functional decline are 
associated with drugs that have a high AC burden in patients with dementia (Kowlanski et al, 
2009).    
Several studies have shown the efficacy of using non-invasive tools to calculate AC burden in 
older adults.  Carnahan et al developed the Anticholinergic Drug Scale (ADS) that calculates 
AC burden based on a rating scale that categorizes medications as “3” known to be highly AC 
to “0” no known AC effects (Carnahan et al, 2006).  This tool was used in this study to 
calculate burden.   
This study evaluated the effects of burden on function, cognition, and behavior in moderate to 
severe dementia patients in a state run psychiatric hospital.  Few studies have investigated the 
effects of AC burden on function in moderate to severe AD patients. This is the only study, to 
the knowledge of the author, to specifically evaluate these effects in a state run hospitalized 
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setting.  Furthermore, few studies have evaluated these effects on behavior and cognition as 
well in this patient population.  This study did not find a statistical association between AC 
burden and functional impairment.  Additionally, a statistical association was not seen with AC 
burden and either cognitive or behavioral outcomes.  One possible reason for this outcome 
could be specific drugs that are not considered to be highly AC according to the ADS but are 
known to cause functional impairment in older adults and dementia patients.  Benzodiazepines 
and antipsychotics have been shown to be associated with negative outcomes in older adults 
and those with dementia (Hilmer et al, 2009), but only a few in each class have AC properties 
according to the SAA assays.   
6.2 Burden Effects on Function 
Much of the evidence of AC burden being associated with poorer outcomes is in older adults 
without dementia.  This is discussed in section 1.2, where much of the evidence is from studies 
in psychiatrically stable older adults.  Furthermore, some of the scales used to quantify burden 
use older adults without dementia or cognitive impairment.  This may be one reason why the 
current study failed to show an association between burden and outcomes.  The studies 
conducted in cognitively stable and community residing older adults are an important starting 
point as much of the inappropriate or AC medication use is not exclusive to this population.  It 
is also not uncommon in nursing homes and hospitals where there are an increasing number of 
moderate to severe dementia patients. In a study by Landi et al, inappropriate medications 
including some that have AC properties were associated with impaired physical performance, 
muscle strength and functional status (Landi et al, 2007).  Inappropriate medications have been 
shown to increase the risk of falls (Nebes et al, 2007) and therefore higher morbidity and 
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mortality in an already vulnerable population.  There are few studies that have investigated the 
association between AC burden and function in dementia patients.  One such study by Sink et 
al, found a decline in higher functioning dementia patients taking AC medications and 
functional impairment.  The decline in the seven components of the activities of daily living 
(ADLs) was 1.62 in patients taking tolterodine and oxybutynin compared 1.08 for those not 
taking the two AC medications (Sink et al, 2008).  The two medications used in the study are 
level 3 AC medications.  The most commonly used medications in this study of moderate to 
severe dementia patients at PGH, used medications that were levels 1 and 2 medications. 
Additionally, while statistical significance was not determined for the association between AC 
burden and function, the results are inconclusive based on the limitations of the study and the 
limited amount of evidence in the literature.   
6.3 Other Effects on Function 
In this study, the model found that there are other variables that affect function including time, 
race, current use of ChEIs or memantine, residence, history of alcohol use, and FCI score.   In 
this study impaired function refers to decreased FIMS scores, therefore some of the 
relationships between the variables and the outcome are not as expected.  Higher FIMS scores 
or improved function was negatively associated with time, White or Black race, and use of 
alcohol.   As time increased function decreased.  Also, decreased functioning was associated 
with White or Black races.  This may not be an accurate relationship as there were only three 
patients who were not classified as White or Black.  Lastly, decreased function was associated 
with current or previous alcohol use.  Positive associations were found with the use of 
memantine or a ChEIs, living at home (with or without assistance) prior to admission to PGH, 
and FCI.  Higher functioning was associated with patients who used memantine or ChEIs.  
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Additionally, those patients that lived at home prior to being admitted to PGH were associated 
with higher functional scores.  The last association was with FCI, the higher the functioning the 
higher number of chronic diseases that affect function.  This association is difficult to follow, 
as more chronic diseases would be expected to decrease functioning not increase it.   
6.4 Effects on Cognition and Behavior 
There are numerous studies that have evaluated cognition in those older adults that have 
received AC medications.  There are fewer studies in dementia adults compared to non-
demented adults, but the results are the same.  Increased AC burden increases cognitive 
impairment, which was described in section 1.2.  This study, however, did not find an 
association between burden and worsening cognition.  This is counterintuitive especially when 
the patients had an average burden score of 3.0.  This is a high score compared to a study by 
Boustani et al, where the average burden scores were 1.7 using the ACB, a tool similar to the 
ADS, in 3013 older adults (Boustani et al, 2008).  Another study, by Kowlanski et al, also had a 
high burden score of 2.55 in dementia patients and did not find an association between 
engagement and burden (Kowlanski et al, 2009).  The study by Sink et al also did not find an 
association between burden and cognition (Sink et al, 2008).  There are several potential 
reasons for this including the use of the ADS to quantify burden, the use of subjective measures 
of cognition quantified as change or no change, the more severe stress of dementia experienced 
by these patients, and possibly the low sample size.   These are described in more detail in 
section 6.5. 
Behavioral problems typically increase as dementia progresses (1), but few studies have 
investigated the increased behavioral problems that are associated with AC medications.  The 
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studies that discuss behavioral problems in dementia patients, usually do so in the context of 
treating them (Edell et al, 2001; Adams et al, 2003).    These studies investigate the use of 
antipsychotic medications and their benefits on behavior.  Some of these antipsychotics have 
AC properties including olanzapine, clozapine, and thioridazine.  It would seem that if AC 
medications impair function and cognition, then behavior would be impaired as well.   In this 
study there was not an association between burden and behavior.  The only study that 
investigated this relationship did so through engagement (Kowlanski et al, 2009).  Where the 
dementia participants with increased burden did not have an association with worsening 
engagement, specifically, increased sleeping, decreased activity, and increased “doing 
nothing.”  Future research will need to determine if there is a link between behavior and AC 
burden in dementia patients.   
6.5 Limitations of Study 
The lack of ability to identify an association, if it exists, between function, cognition, and 
behavior and AC burden may be explained by several factors related to the design of this study 
and the patient population who participated.  The first is that all of the participants were at 
different stages in their disease when they were admitted to PGH.  Severe disease is associated 
with greater functional, cognitive, and behavioral deficits that may mask or provide more 
influence on these outcomes than AC burden.  This was noted in a study by Sink et al that did 
not find an association between AC drug use and cognition in more severe dementia patients 
(Sink et al, 2008).   
A second possibility is the source of the data. Nursing notes in ht medical record are subjective 
in assessing cognition and behavior.  The inter- and intra-variability among nurses makes it 
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inherent that there will be some incorrect interpretations as to the definition of worsening 
behavior.  In one instance, a patient had been moved from one unit to another due to the 
behavioral problems.  The notes from the original unit showed worsening behavior, but when 
transferred the patient’s behavior stabilized with no major improvement or worsening.  Also, 
there was not a widely-used definition employed by the investigator (S. Dharia) to determine 
change.  The use of only one investigator to decipher the notes reduced any bias in the 
interpretation of them.  Hand-writing, was an additional issue as it made some notes difficult to 
interpret.  There are several tools for cognition and behavior in dementia, such as the 
Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) (Rosen et al, 1984) or the 
Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) 
There are some limitations of using the ADS.  This scale may not fully capture AC burden as it 
does not take into account dose.  A study that evaluated the relationship between AC burden 
and decrease engagement in dementia patients used a similar tool to quantify burden, the 
Anticholinergic Burden scale (ACB), did not find an association with burden (Kowlanski et al, 
2009).  One limitation that was noted in the study was the limited precision in the 
categorization of the AC activity by using the 3-point scale (Kowlanski et al, 2009).  
Additionally, the individual differences in absorption, distribution, metabolism and excretion 
(Reisberg et al, 
1987), but most are not appropriate in this setting.  Several are lengthy and time-consuming or 
require the nurse or aide to ask several questions or interview the patient.  Tools such as the 
Severe Impairment Battery (SIB) may be appropriate in this setting (Albert et al, 1992).  Future 
research to develop a tool that allows for the nurse or aide to use direct observation to assess 
behavior and cognition and takes a short amount of time to fill out would be ideal and reduce 
any bias.  
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are considerable.  Using a scale such as the ADS does not take this into account and may 
explain the non-statistically significant result. Also, not taking into consideration dose may 
affect the outcome.  Furthermore, there are several changes in a patient’s medications when an 
individual is admitted to PGH in order to stabilize them.  Many of the medications used are 
antipsychotics that may not be on the ADS scale, even though, these drugs are known to cause 
impaired cognition, behavior and function in older adults (Hilmer et al, 2009).   Lastly, there 
are several methods for estimating burden, all of which have their strengths and weaknesses, 
with no ideal one (Carriere et al, 2009).     
Another factor may have been the small number of patients in the study.  A larger sample may 
provide a significant association.  The sample size calculation performed determined that 436 
patients were needed in order to obtain 80% power in this study.  Increasing the number of 
patients would have been difficult in this situation as each of the five state run mental health 
hospitals do not use the FIMS as a functional assessment tool.  Additionally, not all of the 
hospitals have geriatric centered care.  
An additional limitation of this study is the observational nature of the research as cause and 
effect cannot be established.  While there is much speculation as to the strength of evidence 
from an observational study, an article found that the average results from randomized, 
controlled studies overestimated the magnitude of the associations and the well-designed 
observational ones did not (Concato et al, 2000).  Furthermore, the observational studies 
evaluated, had less variability in the estimates than did the RCTs on the same cardiovascular 
topic.  Therefore, the observational design might not be a true limitation of the study.  
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Much of the dementia research concerning the use of medications with AC properties is 
performed in AD patients specifically.  In this study the original design was to include only AD 
patients, but due to the low number all dementia patients were included.  AD patients appear to 
be at greater risk of negative effects using AC medications due to the etiology of the disease 
and the large proportion of this form of dementia compared to the others.   Yet all dementia 
patients are vulnerable due the significant cognitive impairment associated with the disease. 
6.6 Strengths 
Some of the strengths of this study include the data source.  The use of medical charts provides 
much more information about a participant’s health, medical, and pharmacy data compared to a 
claims database.  Pharmacy or hospital claims data are sometimes used as an information 
source for studies.  In the preliminary research study, section 3.1, the first study described used 
a procedure and diagnosis specific database that while large in size did not include all of the 
pertinent information.    
Additionally, the longitudinal nature of the research is an advantage.  Compared to a cross-
sectional method, this method allows for evaluation of an outcome over time and for a truer 
representation of the relationship between various effects and the outcomes.  It also allows for 
stronger associations to be made between outcomes of interest and specific variables.   
The use of only one student to collect all of the data, except one patient, minimizes any inter-
rater variability that may have occurred.  In addition, when interpreting the subjective nursing 
notes, using only one rater minimized any bias.   
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Lastly, moderate to severe dementia patients are not widely studied, especially those in state-
run psychiatric hospitals.  This study provided knowledge on an underrepresented and 
exceedingly vulnerable population due to their disease and special care.   
6.7 Future Directions 
The majority of the research in the area of AC burden is conducted in older adults that do not 
suffer from dementia.  What little literature there is on dementia and AC burden is mostly in the 
form of case studies or observational studies.   Additionally, many are focused on cognitive 
outcomes.  Future research should make use of experimental designs, specifically an 
interventional study or make use of national disease databases.  This interventional study 
should assess the change or improvement in functional, cognitive, and behavioral impairment 
caused by AC medications as dementia patients are removed from potentially inappropriate 
medications.  Furthermore, different levels of burden should be included, to determine if lower 
burden causes less harm than more burden.  The intervention should be to remove the 
participants from the AC medications and compare them to those who are still currently taking 
the medications over a period of time.  Outcomes should include at least behavior, function, 
and cognition.  A randomized clinical trial (RCT) will provide added evidence as to the 
negative effects or no effects of AC burden on dementia patients.   Moreover, an RCT will 
provide a better estimate of the potential causal relationship between AC burden and outcomes.  
Additionally, the use of a large disease database will have to wait until they have been 
completed as they are still in the process of being developed.  One potential problem with this 
proposed study is the recruitment of patients.  As mentioned in sections 1.4 and 3.2, 
recruitment of older adults and those with dementia is a barrier to conducting research 
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including experimental and prospective observational studies.  Overcoming this barrier is 
imperative to further research in the area of dementia.  
6.8 Conclusions 
The effect of AC medications on moderate to severe dementia patients is not fully understood. 
The minimal amount of literature on this association, suggests that AC burden may have 
negative consequences on function, cognition and behavior in dementia patients.  This study 
provided inconclusive evidence to this current theory that AC burden negatively impacts 
function, cognition, and behavior in dementia patients.  To further this area of research, 
overcoming recruitment barriers is essential.  
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Appendix A: Patient Intake Form 
Subject #: ________ 
Cognitive, Functional and Behavioral Outcomes Associated with Anticholinergic Drug 
use in Alzheimer's disease Patients Taking Cholinesterase Inhibitors 
Participant Demographic Form: Please answer the following questions concerning the patient 
to the best of your ability.  If you have concerns about any of the questions please let us know 
at the first visit.   
1. Date of Birth (MM/DD/YYYY): ________________ 
 
2. Age (in years): ___________ 
 
3. Sex (check one):     
___Male 
___Female   
4. Marital Status (check one): 
___Married 
___Single 
___Divorce 
___Other 
5. Ethnicity (check one):   
___White 
___Black  
___Hispanic  
___Asian/Pacific Islander  
___American Indian/Alaskan Native  
___Other/Not Specified 
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6. Residence (check one):    
___Home 
___Assisted Living Facility 
___Other 
 
7. How long have you lived at your current residence: 
______________________________ 
 
8. Primary care doctor: _________________________________________ 
 
9. Have you ever participated in a study or clinical trial (check one): 
___Yes 
___No 
10. Highest Grade Achieved (check one):  
___Elementary School 
___Middle School 
___High School 
___College 
___Graduate 
11. Current Smoker (check one):      
___Yes 
___No 
If yes, how many years: ____  
     In addition, how many cigarettes per day: ____ 
12. If no, did you smoke previously (check one):    
___Yes 
___No 
If yes, how long ago: ____  
     In addition, how many cigarettes per day: ____ 
13. Current Diagnoses (check as many as apply):  
 130 
 
___Parkinson’s Disease   ___Diabetes 
___Urinary Incontinence    ___Thyroid Problems 
___Abdominal Cramps    ___Clots 
___Diarrhea      ___Depression 
___Wear Eyeglasses    ___Alcohol Problems 
___Use Hearing Aids    ___Seizures 
___Vomiting      ___Arthritis 
___Nausea     ___Cancer 
___Loss of Appetite    ___High Blood Pressure 
___Increase Heart Rate   ___Confusion 
___High Cholesterol    ___Head Trauma 
___Heart Murmur    ___Loss of Coordination 
___Arrhythmias    ___Dry Mouth 
___Asthma     ___Constipation 
___Pneumonia    ___Agitation 
14. Do you have a family history of the following disorders or illnesses: 
___Parkinson’s Disease   ___Alzheimer’s Disease 
___High Cholesterol    ___Thyroid Problems 
 ___Diabetes     ___Anemia 
 ___Cancer     ___Arrhythmias 
 ___High Blood Pressure   ___Heart Murmur 
15. When were you diagnosed with AD (MM/DD/YYYY): __________________ 
16. Which medication for AD are you currently taking (check all that apply): 
___Aricept 
___Exelon 
___Razadyne 
___Namenda 
17. How long have you been taking the above medication (years): ______ 
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18. Were you previously on a different medication for AD (check one): 
___Yes 
___No 
19. If yes, which one (check all that apply): 
___Aricept 
___Exelon 
___Razadyne 
___Namenda 
20. Do you think your current AD medication is working (check one): 
___Yes 
___No 
21. Please list all current medications (please back of this page if you run out of space): 
 
Name  Indication  Route  Dosage How often taken 
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
______________________ 
22. Please list all current Supplements/Vitamins/Herbals/OTC (please back of this page if 
you run out of space): 
 
Name  Indication  Route  Dosage How taken 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
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_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
___________________ 
23. Do you think these medications are working (check one): 
___Yes 
___No 
24. If not, please list which ones are not working: 
__________________________________ 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
______ 
25. Approximately how much is your annual out of pocket expenditure on medications and 
supplements : ________ 
26. What type of prescription drug insurance do you have (check all that apply): 
___Medicare part D 
___Medicaid 
___Both 
___Other 
If other, please indicate: 
____________________________________________________ 
27. On how many days per week do you eat red meat: _____ 
28. What kind of physical exercise do you do (check all that apply): 
___Aerobics 
___Weight-lifting 
___Walking 
___Running/Jogging 
___Cycling 
___Swimming 
___Other 
If other, please indicate: 
____________________________________________________ 
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29. What kinds of activities do you enjoy (examples - memory games, gardening, 
crossword puzzles): ________________________________________________ 
_________________________________________________________________________
_________________________________________________________________________ 
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Appendix B: Anticholinergic Drug Scale 
Level 3 Drugs 
Amitriptyline, dicyclomine, oxybutynin, atropine, dimenhydrinate, procyclidine, benztropine, 
diphenhydramine, promethazine, brompheniramine, doxepin, propantheline, carbinoxamine, 
flavoxate, protriptyline, chlorpheniramine, hydroxyzine, pyrilamine, chlorpromazine, 
hyoscyamine, scopolamine, clemastine, imipramine, thioridazine, clomipramine, meclizine, 
tolterodine, clozapine, nortriptyline, trihexyphenidyl, darifenacin, orphenadrine, trimipramine, 
desipramine 
Level 2 Drugs 
Carbamazepine, disopyramide, molindone, cimetidine, loxapine, oxcarbazepine, 
cyclobenzaprine, meperidine, pimozide, cyproheptadine, methotrimeprazine, ranitidine 
Level 1 Drugs 
Alprazolam, divalproex sodium, olanzapine, amantadine, estazolam, oxazepam, ampicillin, 
famotidine, oxycodone, azathioprine, fentanyl, pancuronium, bromocriptine, fluoxetine, 
paroxetine, captopril, fluphenazine, perphenazine, cefamandole, flurazepam, phenelzine, 
cefoxitin, fluticasone-salmeterol, piperacillin, cephalothin, fluvoxamine, prednisolone, 
chlordiazepoxide, furosemide, prednisone, chlorthalidone, gentamicin, prochlorperazine, 
clindamycin, hydralazine, sertraline, clonazepam, hydrocortisone, temazepam, clorazepate, 
isosorbide, theophylline, codeine, isosorbide dinitrate, thiothixene, cortisone, isosorbide 
mononitrate, tramadol, cycloserine, ketotifen, ophthalmic triamcinolone, cyclosporine, 
loperamide, triamterene, dexamethasone, lorazepam, triazolam, diazepam, methylprednisolone, 
trifluoperazine, digitoxin, midazolam, valproic acid, digoxin, morphine, vancomycin, diltiazem, 
nifedipine, warfarin, dipyridamole, nizatidine, 
Level 0 Drugs 
Acarbose, acetaminophen, acetaminophen/dichloralphenazone/isometheptene, acetazolamide, 
acetic acid topical, acyclovir, adenosine, albuterol, alendronate, allopurinol, aluminum 
carbonate, aluminum hydroxide, amiloride, amiodarone, amlodipine, ammonium lactate 
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topical, amoxicillin, amoxicillin-clavulanate, anagrelide, anastrozole, anileridine, apraclonidine 
ophthalmic, ascorbic acid, aspirin, atenolol, atorvastatin, azithromycin, bacitracin ophthalmic, 
bacitracin topical, baclofen, balsam Peru topical, beclomethasone, beclomethasone nasal, 
benazepril, benzocaine topical, benzonatate, beta-carotene, betamethasone topical, 
betamethasone-clotrimazole topical, betaxolol ophthalmic, bethanechol, bicalutamide, 
bisacodyl, bismuth subsalicylate, bisoprolol, brimonidine ophthalmic, brinzolamide 
ophthalmic, budesonide, budesonide nasal, bumetanide, bupropion, buspirone, butabarbital, 
butalbital, caffeine, calamine topical, calcipotriene topical, calcitonin, calcitriol, calcium 
acetate, calcium and vitamin D, calcium carbonate, camphor-menthol topical, candesartan, 
carbachol ophthalmic, 
carbamide peroxide otic, carbidopa, carisoprodol, carvedilol, casanthranol, 
casanthranoldocusate, cascara sagrada, castor oil, cefaclor, cefazolin, cefixime, ceftibuten, 
ceftriaxone, cefuroxime, elecoxib, cephalexin, cerivastatin, cetirizine, cetylpyridinium topical, 
chloral hydrate, chlorambucil, chlorhexidine topical, chlorothiazide, chlorpropamide, 
chlorzoxazone, cholestyramine, chondroitin, ciclopirox topical, cilastatin, cilostazol, 
ciprofloxacin, cisapride, citalopram, clarithromycin, clavulanate, clindamycin topical, 
clobazam, clodronate, clonidine, clopidogrel, clotrimazole, cloxacillin, colchicines, colestipol, 
collagenase topical, conjugated estrogens, cranberry, cromolyn, cyanocobalamin, 
cyclophosphamide, danazol, dantrolene, demeclocycline, desmopressin, desonide topical, 
desoximetasone topical, dexamethasone nasal, dexamethasone ophthalmic, dexamethasone 
topical, dextromethorphan, diclofenac, dienestrol topical, diflunisal, dihydroxyaluminum 
sodium carbonate, diphenoxylate, dipivefrin ophthalmic, dirithromycin, dobutamine, docusate, 
donepezil, dopamine, dorzolamide ophthalmic, doxazosin, doxycycline, duloxetine, econazole 
topical, edrophonium, enalapril, enoxaparin, entacapone, epoetin alfa, ergocalciferol, ergoloid 
mesylates, erythromycin, escitalopram, esomeprazole, esterified estrogens, estradiol, estradiol 
topical, estropipate, ethambutol, ethinyl estradiol, etidronate, etodolac, felbamate, felodipine, 
fenofibrate, ferrous gluconate, ferrous sulfate, fexofenadine, filgrastim, finasteride, flecainide, 
fluconazole, fludrocortisone, flumazenil, flunisolide, fluocinonide topical, fluoride topical, 
fluorometholone ophthalmic, flutamide, fluticasone, fluvastatin, folic acid, fosinopril, 
gabapentin, galantamine, gemfibrozil, gentamicin ophthalmic, gentamicin topical, ginkgo, 
glimepiride, glipizide, glucagons, glucosamine, glyburide, glycerin topical, guaifenesin, 
guanfacine, halcinonide topical, haloperidol, heparin, hydrochlorothiazide, hydrocodone, 
hydrocortisone ophthalmic, hydrocortisone otic, hydrocortisone topical, hydromorphone, 
hydroxychloroquine, hydroxypropyl, methylcellulose ophthalmic, hydroxyurea, ibuprofen, 
imipenem, indapamide, indomethacin, insulin, ipratropium, irbesartan, iron polysaccharide, 
isoniazid, isradipine, ketoconazole topical, ketoprofen, labetalol, lactase, lactulose, lamotrigine, 
lanolin-mineral oil topical, lansoprazole, latanoprost ophthalmic, leuprolide, levobunolol 
ophthalmic, levodopa, levofloxacin, levothyroxine, lidocaine, lindane topical, liothyronine, 
lisinopril, lithium, loratadine, losartan, loteprednol ophthalmic, lovastatin, LVP solution, 
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Lysine, Magnesium preparations, mannitol, medroxyprogesterone, megestrol, meprobamate, 
mesalamine, metaxalone, metformin, methazolamide, methenamine, methotrexate, 
methyclothiazide, methylcellulose, methyldopa, methylene blue, methylphenidate, 
methylprednisolone topical, methyltestosterone, metoclopramide, metolazone, metoprolol, 
metronidazole, mexiletine, miconazole topical, midodrine, mineral oil, minocycline, 
mirtazapine, misoprostol, moexipril, mometasone nasal, montelukast, moxifloxacin, 
multivitamin, mupirocin topical, nabumetone, nadolol, naloxone, naproxen, nateglinide, 
nefazodone, neomycin ophthalmic, niacin, nisoldipine, nitrofurantoin, nitroglycerin, 
norepinephrine, norfloxacin, nystatin, octreotide, ofloxacin, olopatadine ophthalmic, 
omeprazole, oxymetazoline nasal, pamidronate, pancrelipase, pantoprazole, papaverine, 
penicillin, pentoxifylline, pergolide, perindopril, permethrin topical, petrolatum topical, 
phenazopyridine, Phenobarbital, phenyl salicylate, phenylephrine, phenylpropanolamine, 
phenytoin, phytonadione, pilocarpine ophthalmic, pindolol, pioglitazone, pirbuterol, piroxicam, 
pivampicillin, polycarbophil, polyethylene glycol electrolyte solution, polymyxin B 
ophthalmic, potassium bicarbonate, potassium chloride, potassium citrate, pramipexole, 
pramoxine topical, pravastatin, prazosin, prednisolone ophthalmic, primidone, probenecid, 
procainamide, progesterone, propafenone, propoxyphene, propranolol, propylthiouracil, 
pseudoephedrine, psyllium, pyrazinamide, pyridostigmine, quetiapine, quinapril, quinidine, 
quinine, rabeprazole, raloxifene, ramipril, repaglinide, reserpine, rifampin, rimantadine, 
rimexolone ophthalmic, risedronate, risperidone, rofecoxib, ropinirole, rosiglitazone, salicylic 
acid topical, salmeterol, salsalate, selegiline, selenium sulfide topical, senna, silver sulfadiazine 
topical, simethicone, simvastatin, sodium bicarbonate, sodium chloride, sodium phosphate, 
sodium sulfacetamide ophthalmic, sotalol, spironolactone, succinylcholine, sucralfate, 
sulfamethizole, sulfamethoxazole, sulindac, tacrine, tamoxifen, tamsulosin, terazosin, 
terbinafine topical, terbutaline, terconazole topical, tetracycline, thiamine, thyroid desiccated, 
ticlopidine, timolol, tobramycin ophthalmic, tolbutamide, tolcapone, topiramate, torsemide, 
trandolapril, trazodone, triamcinolone nasal, triamcinolone topical, trichlormethiazide, 
triethanolamine, polypeptide, oleate otic, trimethoprim, troglitazone, trypsin, tuberculin 
purified protein derivative, ursodiol, valsartan, vecuronium, venlafaxine, verapamil, vitamin E, 
zafirlukast, zaleplon, zinc gluconate, zinc sulfate, zolpidem, zopiclone 
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Appendix C: PGH Letter of Consent 
March 31, 2010 
[Mr/Mrs. Patient/AR] 
[Street Address] 
[City, State  ZIP] 
RE: [Patient name/Reg. No.] 
Dear [Mr./Mrs. Patient/AR]: 
Piedmont Geriatric Hospital has been contacted by a Virginia Commonwealth University (VCU) 
graduate student, Sheetal Dharia, who is working toward her doctorate in Pharmacy.  She is interested 
in using our data for a research project designed to evaluate the possible effects of the use of a 
combination of medications that are for health conditions other than Alzheimer’s disease or dementia 
on the functional and cognitive status of people who have dementia.  
The goals of this project are: 
1) To better understand what happens when people with dementia take multiple medications 
2) To improve how medications are used in the future for patients with dementia  
The student is requesting access to medical and prescription information from the records of the 
above named patient.  Any identifiable information such as name, date of birth, admission and 
discharge dates will not be collected or published for this project.  We are notifying you in advance in 
order to give you an opportunity to agree or object to the record being accessed for this purpose. 
Enclosed you will find a list of the information that will be collected, and an authorization form to sign 
if you wish to grant permission for this project.  If, however, you object to participation in this research 
project, please simply write “I object” at the top of the form and leave the form unsigned.  Please 
return the form in the enclosed envelope by April 15, 2010.  If we have not received a response by 
April 19, 2010, we will interpret the lack of response to mean there is no objection.  If you have 
concerns that you would like to discuss regarding this project, please contact me at (434)767-4411. 
Sincerely, 
Peggy S. Vaughan 
Health Information Manager 
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Research Information Sheet 
 
 
 
Focus of 
Research: 
 Evaluate possible effects of the combination of medications that are for health conditions 
other than Alzheimer’s disease or dementia on the functional and cognitive status of 
people with dementia 
Information 
Collecting: 
 
 
 Medications 
 Scores for thinking and functioning (Nursing documentation) 
 Sex 
 Marital Status 
 Age 
 Race/Ethnicity 
 Length of Stay at Piedmont Geriatric Hospital 
 Number of hospitalizations at Piedmont Geriatric Hospital 
 Education (highest grade completed) 
 Smoking (No/Yes), if yes-how many cigarettes each day? How many years? 
 Drinking (No/Yes), if yes-how much alcohol each day? How many years? 
 When dementia was diagnosed 
 
 
AUTHORIZATION FOR USE/DISCLOSURE/EXCHANGE OF PROTECTED HEALTH INFORMATION 
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DBHDS Facility Name:  Piedmont Geriatric Hospital 
Telephone Number: 434-767-4401 Fax: 434-767-4404 
Patient Name  (Last, First, MI):    
DOB:     SS# (optional)       
Extent or nature of use/disclosure is limited to: (Check √ or list all that apply) 
Discharge Summary History & Physical Social Work Assessment 
Psychiatric Evaluation Progress Notes  Physician Orders 
Lab Work Consultations Treatment Plan 
HIV/AIDS Information Substance Abuse Information Psychological Evaluation  
Other: Medications, Functional scores, sex, marital status, age, race/ethnicity, length of stay, number of hospitalizations at 
PGH, education, information regarding smoking/drinking, when dementia was diagnosed 
Specified purpose or need for use/disclosure is:  Diagnosis/Treatment   Discharge Planning   Other, Specify Research 
project for a pharmacy graduate student to acquire a doctorate degree. 
 
Permission is hereby given to: Piedmont Geriatric Hospital 
5001 East Patrick Henry Highway 
Burkeville, VA  23922 
Facility Name & Name of Responsible 
Person e.g. (“Facility director or his 
authorized designee”) 
 To disclose information to   OR   
 To exchange information with: 
Sheetal Dharia /Patricia Slattum, PharmD, PhD/ VCU School of Pharmacy 
Department of Pharmacotherapy and Outcome Science 
410 North 12th
Richmond, VA  23298-0581 
 Street / P. O. Box 980581 Name, or other specific identification 
and organization  
Street Address, City, State, Zip                  
Phone/Fax #  Phone:  (804)828-6355                             Fax:  (804)828-1815 
I also authorize the recipient to use the information received pursuant to this authorization. 
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As the person signing this authorization, I acknowledge that I am giving my permission to the above-named person/class of 
persons to disclose and use protected health information.  I further acknowledge that: 
• I may refuse to sign this authorization. 
• DBHDS/ Piedmont Geriatric Hospital cannot condition the provision of treatment to me on my signing of this authorization. 
• The original or a copy of this authorization shall be included with my original records. 
• I have the right to revoke this authorization at any time, except to the extent that action has been taken in reliance on it, by 
delivering the revocation in writing to the provider who is in possession of my health care records. 
• There is a potential for any information disclosed pursuant to this authorization to be subject to re-disclosure by the recipient and, 
therefore, no longer protected by the provisions of the HIPAA Privacy Rule.  If this information is being disclosed from records 
protected by the Federal substance abuse confidentiality rules (42 CFR part 2), the Federal rules prohibit the recipient from making 
any further disclosure of this information unless further disclosure is expressly permitted by your written authorization or as 
otherwise permitted by 42 CFR part 2.  A general authorization for the release of medical or other information is NOT sufficient for 
this purpose.  The Federal rules restrict any use of the information to criminally investigate or prosecute any alcohol or drug abuse 
patient. 
If not previously revoked, this authorization will expire in:  90 Days  One Year     Upon project completion 
The information may be disclosed effective:  Immediately  (specify date)       
This authorization  does  does not extend to information placed in my record after the date I signed this form. 
   
Signature of Individual (adult) or Legally Authorized Representative Relationship Date Signed 
  
Signature of Minor (if required by law) Date Signed 
  
Witness (optional) Date Signed 
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Appendix D: PGH Collection Form 
   Subject Number:  
Subject Collection Form  
       
Age    Smoker Yes No Previous 
   How long (years)?       
Sex: M=0; F=1     
How Many 
Cigarettes/Day?       
   Alcohol    
Marital Status 
  
 
How many drinks per 
day?       
Married=1  How long (years)?       
Single=2      
Widowed=3  
Highest Grade 
Achieved (Check 1) < K-5 K-5  6-8 
Divorced=4   9-12 > 12+ Other: 
Separated=5      
Unknown=9  Date of Diagnosis     
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Ethnicity/Race:                              
White=1;                                                          
Black=2;                                        
Hispanic=3;                                            
Asian/Pacific Islander=4;         
American Indian=5;                                           
Unknown=9    
Residence (prior to 
admission):                   
Home (No 
Assistance)=1; 
Home(w/Assistance)=2;              
ALF=3;                                           
SNF=4;                                           
Unknown=9     
        
Length of Stay    # of Admissions     
       
Alzheimer's Treatment:                         
Aricept=1;                                                   
Exelon=2;                                            
Razadyne=3;                         
Namenda=4                                        
Unknown=9                                                           
Yes ___                  
No ___      
Previous 
___ 
Dose per day: 
    
Admission conditions:                   
Absent=0;                                           
Present=1;                                            
Unknown=9       
HTN   Constipation   Seizures    
Bradycardia   
Abdominal 
Cramps    
Loss of 
Coordination    
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Tachycardia   Vomiting   
Confusion/ 
Delirium    
Arrhythmias   
Urinary 
Incontinence   Depression    
Other CV   Nausea   Agitation    
Asthma   Loss of Appetite   TBI    
Pneumonia   Diarrhea    
Parkinson's 
Disease    
COPD   Dry Mouth   Clots (Any)    
Cancer   High Cholesterol   Other:  
Wear Eyeglasses   Diabetes    
Use Hearing Aids    Thyroid Problems    
       
 FIMS 
Cognitve 
Problems Behavioral Problems ADS Score   
Date Score Yes=1;  No=2      Yes=1;  No=2          
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